










The handle http://hdl.handle.net/1887/48287 holds various files of this Leiden University 
dissertation 
 
Author: Schaarenburg, R.A. van 
Title: The role of C1q in (auto) immunity 
Issue Date: 2017-04-12 
The role of C1q in (auto) immunity
Rosanne Annelies van Schaarenburg
The role of C1q in (auto) immunity
©Rosanne van Schaarenburg, 2017
All rights are reserved. No part of this thesis may be reproduced, stored, or transmitted in any form or by 
any means without permission of the copyright owners.
Cover design:   Arthur de Haan
ISBN:   978-94-6295-590-5
Printing:   ProefschriftMaken Vianen
The research described in this thesis was performed at the department of Rheumatology of the Leiden 
University Medical Center, Leiden University, Leiden, The Netherlands. The research was supported by 
the Dutch Organization for Scientific Research (Vidi grant).
Financial support by the NVLE foundation for the publication of this thesis is gratefully acknowledged.
Printing of the thesis was also financially supported by the Leiden University Medical Center, Leiden 
University and Inova Diagnostics.
The role of C1q in (auto) immunity
Proefschrift
Ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus Prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 12 april 2017
Klokke 11:15 uur
door
Rosanne Annelies van Schaarenburg
geboren te Zoeterwoude
in 1988
Promotores:    Prof. Dr. R.E.M. Toes
    Prof. Dr. T.W.J. Huizinga
Co-promotor:   Dr. L.A. Trouw
Leden promotiecommissie: Prof. Dr. C. Van Kooten, Universiteit Leiden
    Prof. Dr. A.C. Lankester, Univeristeit Leiden
    Dr. D. Wouters, Sanquin Amsterdam
    Dr. G.M. Steup-Beekman, Universiteit Leiden
    Dr. S.H.M. Rooijakkers, Universiteit Utrecht
    Prof. Dr. P.W.H.I. Parren, Univeristeit Leiden
Voor mijn Ouders

Chapter 1 Introduction 9
Part I The clinical association of C1q and anti-C1q 35
Chapter 2 Identification of a novel non-coding mutation in C1qB 
in a Dutch child with C1q deficiency with recurrent 
infections
Immunobiology, van Schaarenburg 2015 
37
Chapter 3 Marked variability in clinical presentation and outcome 
of patients with C1q deficiency
J Autoimmun, van Schaarenburg 2015
53
Chapter 4 C1q deficiency and neuropsychiatric systemic lupus 
erythematosus
Frontiers Immunol, van Schaarenburg & Magro-Checa 2016
67
Chapter 5 Complement activation and anti-C1q autoantibodies 
in patients with neuropsychiatric systemic lupus 
erythematosus
Lupus, van Schaarenburg & Magro-Checa 2016
85
Part II The local production of C1q by immune and non-
immune cells
105
Chapter 6 The production and secretion of complement 
component C1q by human mast cells
Mol. Immunol. van Schaarenburg 2016
107
Chapter 7 Human chondrocytes produce and secrete C1q
Manuscript in preparation
123
Chapter 8 Summary and discussion 137











C1q, antibodies and anti-C1q autoantibodies.
Immunobiology. 2015 Mar;220(3):422-7
Autoantibodies against complement components and functional 
consequences.
Mol Immunol. 2013 Dec 15;56(3):213-21.
Anti-C1q autoantibodies, novel tests, and clinical consequences.







The immune system plays an important role in protecting the body against infectious 
agents. The immune response is delicately regulated and should only be initiated 
when necessary. This also requires timely termination, since inappropriate immune 
activation can result in persistent inflammatory disease or autoimmunity [1]. The 
immune system can be divided into the innate system and the adaptive system. 
The innate immune system is the first line of defence that provides a quick non-
specific response compared to the adaptive immune system. The adaptive immune 
response is a specific response that is mainly established by two cell types, the B 
and T cells. The B cells are able to recognize their antigen in their native form. The 
antigen recognition together with activation signals will activate the B cells and 
differentiate them in antibody secreting plasma cells [2]. T cells are responsible 
for producing these activation signals, but are also able to produce inflammatory 
cytokines and kill infected cells. In contrast with B cells, T cells are only able to 
recognize processed antigens presented by antigen presenting molecules also 
known as the human leukocyte antigens (HLA) [3]
The innate immune system
The innate part of the immune system is known to respond quickly and non-
specifically. Behind the mechanical and biological barriers, including the skin and 
mucus in the lungs and intestine, innate immune cells can be activated in case of 
infection with a pathogen. The innate immune cells can be triggered via pattern 
recognition molecules (PAMPS) or via signals of damaged and stressed cells called 
danger-associated molecular pattern molecules (DAMPS). Characteristics of the 
innate immune system are activation of the complement system, the recruitment and 
activation of immune cells by cytokines, recognition and clearance of pathogens in 
the tissue, and induction of the adaptive immune response via antigen presentation. 
Innate immune cells are, amongst others,  macrophages, dendritic cells, neutrophils, 
mast cells, basophils and natural killer cells. The complement system is seen as a 
part of the innate immune system because the activation of the complement system 
can be quick and non-specific. Macrophages, dendritic cells and mast cells are 
important cells in the production of complement components and thereby also 




Macrophages are large mononuclear phagocytic cells that are able to present 
antigens, but are also very important to engulf and degrade cellular debris and 
pathogens. Myeloid progenitor cells are derived from the bone marrow that 
differentiate into monocytes. The monocytes will migrate into tissues were they can 
maturate towards macrophages. One of the important functions of the macrophage 
is to engulf and to kill microorganisms. Macrophages were identified in the 70’s as 
major producers of C1q [8]. Next to macrophages, it is now known that immature 
dendritic cells are also a major source of C1q production [9, 10]. C1q produced by 
macrophages and dendritic cells play an important role in the clearance of dead 
cells and cellular debris [11, 12].
Dendritic cells
Dendritic cells (DCs) are derived from the same myeloid progenitor cells as 
macrophages and are the most potent antigen-presenting cells (APCs). Derived 
from the bone marrow, monocytic cells travel through the circulation into the 
tissue where they become immature DCs. In the tissue, the immature DCs are 
able to interact with microbial-associated molecules that can activate the DCs. 
Subsequently, DCs can migrate towards secondary lymph nodes under influence 
of cytokines and chemokines. During the migration the DCs will undergo a process 
of maturation. After entering the lymph nodes, the DCs are capable to present 
antigens in combination with co-stimulatory molecules resulting in T-cell activation. 
Immature DCs are an important source of C1q production and after reaching a 
mature stage, the C1q production is diminished [9, 10].
Mast cells
Mast cells (MCs) are best known for their role in anaphylactic allergy responses 
and to protect the body against parasitic worms. They are predominantly present 
in mucosal and skin surfaces and thereby close to the host/environment interface 
[13-15]. As effector cells they can also play an important role in other diseases like 
atherosclerosis, contact dermatitis, cancer and arthritis [16-19]. One of the markers 
of MCs is the high affinity IgE receptor (FcεRI). Via this receptor MCs can become 
activated followed by degranulation. As IgE is already bound to the high-affinity 
FcεRI, crosslinking is of FcεRI is a quick process leading to a swift activation of 
MCs. Degranulation can also occur after triggering by the complement components 
C3a and C5a. Interaction of C3a or C5a with mast cells will activate the mast cells 





The complement system is an essential part of the innate immune system of the 
human body. It consists of a set of soluble proteins, mainly present in blood and 
other body fluids, as well as an intricate system of membrane bound complement 
receptors and regulators. Complement activation can take place via three distinct 
pathways; the classical pathway, the lectin pathway and the alternative pathway. 
Each pathway is activated in a different manner. Together, the complement system 
consists around 30 proteins and via a cascade of enzymatic reactions it results in 
the production of biologically active fragments.
The three pathways have their own activation and recognition mechanisms that 
lead to the formation of C3 convertases where the central complement component 
C3 will be cleaved into anaphylatoxin C3a and opsonin C3b. After formation of 
the C3 convertases C4b2a or C3bBb, the terminal pathway will be initiated, which 
starts with the formation of a C5 convertase. This convertase cleaves C5 into C5b 
and the anaphylatoxin C5a. The fragment C5b will interact with C6 and C7 and form 
a complex, which is able to bind to cell membrane where it can interact with C8 
that will insert into the cell membrane. To form a lytic pore, several C9 fragments 
are needed and will finally form the terminal complement complex (TCC, C5b9, 
membrane attack complex (MAC)) (Figure 1).
Classical pathway
The initiator molecule C1q, which forms, together with the serine proteases C1r and 
C1s, the C1 complex, activates the classical pathway. C1q can bind to different 
ligands like antigen-bound IgG and IgM, apoptotic cells, cellular debris and acute 
phase proteins. When C1q binds to a ligand it undergoes a conformational change, 
which allows the serine proteases C1r and C1s to become activated. The serine 
protease C1s will subsequently cleave C4 into C4a and C4b. The covalent binding 
of C4b follows this on the target together with C2a, which is a cleavage product 
of C2 that is cleaved by C1s into C2a and C2b, forming the C4b2a complex. This 
classical pathway C3-convertase cleaves C3 in to C3a and C3b. C3b can covalent 
bind to its target and C3b act as a opsonin, C3a functions as an anaphylotoxin. 
After the formation of the C3 convertase the C5 convertase will be formed, leading 
to the formation of the terminal pathway [24].
Introduction | 13
1
Figure 1. Activation pathways of the complement system. The central complement component C3 
is activated via three pathways. The classical pathway is activated by binding of immune surveillance 
molecules on the activating surface different from the lectin pathway that is initiated by carbohydrate 
residues on the activating surface. Direct binding of C3b to the activating surface triggers the alternative
pathway. All the three pathways lead to an enzymatic convertases that cleaves C3 (into C3a and C3b) 
either C5 (into C5a and C5b). Furthermore, C5b triggers the terminal pathway, which lead to the formation 
of a multimeric membrane attack complex (C5b-9), resulting in a pore in the target cell membrane.
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The lectin pathway acts in a similar way in activation as the classical pathway 
because the recognition molecule of the lectin pathway, mannose-binding lectin 
(MBL) is structurally highly related to C1q and interacts also with serine proteases. 
However, it recognizes other targets. The lectin pathway will be activated by the 
recognition of certain carbohydrates ligands by mannose binding lectin (MBL) as 
well as H-ficolin or L-ficolin. When MBL is bound to mannose residues on pathogens, 
serine proteases (MASPs) will become activated in the same manner as C1r and 
C1s. The MASPs associated with MBL are MASP-1, MASP-2 and MASP-3.  MASP-
2 is responsible for activating C4 and C2 will generate the C3 convertase C4b2a, 




The alternative pathway is spontaneously activated by hydrolysis of C3 in the 
circulation. This activation process is also known as “tick-over”. Here, C3 is 
spontaneously hydrolysed into C3(H20) or C3i. This hydrolysis can be amplified 
when C3 is interacting with biological and artificial interfaces like gas bubbles, 
biomaterial surfaces, and lipid surfaces and complexes [25-28]. Upon hydrolysis 
the C3 conformation changes allowing factor B (FB) to bind to C3(H20). This will 
be cleaved by the serine proteases Factor D (FD) resulting in the cleavage product 
C3(H20)Bb. This C3-convertase is able to continuously cleave C3 into C3a and C3b 
fragments. In the presence of an activating surface, C3b will covalently bind to the 
surface and initiate a positive feedback loop to the alternative pathway [28]. 
Complement regulation
During activation of the complement system several regulators are involved. In the 
classical pathway and the lectin pathway the soluble regulator C1 inhibitor (C1-INH) 
plays a role. The major role of C1INH in the complement system is the inhibition of 
proteases including as C1s, C1r and MASP2 [29, 30]. Furthermore, C1-INH is also 
able to interfere with the interaction of C3b with FB via a reversible interaction and 
inhibit the alternative pathway [31]. Further down the classical pathway, complement 
regulators like C4b-binding protein (C4BP), Complement Receptor type 1 (CR1) 
and Decay-Accelerating Factor (DAF, CD55), which all can bind to C4b and to C3b 
and can inhibit further activation of the classical and the lectin pathway [32-34]. 
In the alternative pathway the major fluid phase complement regulators are Factor 
H (FH), and properdin [35]. Factor H acts as a co-factor of Factor I mediating the 
cleavage of C3 and decay accelerating activities for the alternative pathway C3 
convertases [36]. Properdin regulates the alternative pathway by stabilizing the 
short lived C3 convertase C3bBb [37]. Furthermore, the alternative pathway can be 
regulated on the cell surface including, membrane co-factor protein (MCP, CD46), 
Complement receptor 1 (CR1, CD35) and DAF. MCP acts as a co-factor for factor I 
and thereby mediates the cleavage of C3b and C4b. CR1 is a receptor for C3b and 
C4b and enhances the phagocytic activity of neutrophil-mediated phagocytosis 
[38]. DAF can accelerate the decay of C3 convertases as described above, but is 
also able to accelerating the decay of C5 convertases [33, 39].
The terminal pathway of the complement system will result in the formation of the 
MAC. During this formation several regulatory proteins can regulate this process. 
CD59, vitronectin and clusterin are regulatory proteins that inhibit the formation of 
the MAC [40-42]. 
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Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus (SLE) is an autoimmune disease, which can affect 
various organs and thereby can be characterized by clinical features including 
glomerulonephritis, rashes, serositis, haemolytic anaemia, thrombocytopenia and 
the central nervous system can also be involved. SLE is characterized by B-cell 
hyper-activation, autoantibody production and immune complex formation [43, 
44]. Patients with SLE have a long list of clinical presentations, which can make it 
difficult for the clinician to diagnose the patient with SLE. The American College of 
Rheumatology (ACR) established a set of criteria for the diagnosis of SLE as well 
as for reasons of scientific research [45]. Overall 20-150 in 100.000 people are 
affected by SLE and it predominantly affects women (80%) [46]. 
The exact aetiology of SLE is unknown but it involves different factors like the 
genetic background and environmental factors [47, 48]. Deficiencies in the classical 
pathway of the complement system is highly associated with the development of 
SLE [49]. In C1q deficiency around 80% will develop lupus, in C1r/C1s deficiency 
the lupus incidence is around 68%, in C4 deficiency 75% and in C2 deficiency 
10%[50-52].
Antibodies against a wide variety of self-antigens are present in SLE patients. Some 
of these autoantibodies can be already present in serum years before onset of 
disease [53]. Many of the antibodies are targeting nuclear antigens and are known 
as anti-nuclear antibodies (ANA’s) [53]. ANA’s can be divided into several subtypes 
including anti-dsDNA antibodies, anti-Ro antibodies, anti-histone antibodies, anti-
Sm antibodies and anti-hnRNP antibodies. Other autoantibodies, which can be 
present in SLE patients, are directed against complement components like C1q 
(anti-C1q) or anti-C1s antibodies [54, 55].
 In the circulation autoantibodies can form immune complexes and deposits in 
tissues like the skin or the kidney or immune complexes can form locally in tissues. 
Studies show that SLE patients have higher immunoglobulins in serum compared 
to healthy controls which correlates with disease activity [56].
Due to the unknown cause and complexity of SLE, patients are mainly treated 
on an individual basis. Most of the patients receive immunosuppressive drugs 
like prednisone. In case of deficiency in a complement component like C1q, 
patients benefit from treatment with Intra-venous Immuno-Globulins (IVIG) [57] 
and fresh frozen plasma [58]. A more radical treatment is Haematopoietic Stem 




Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)
One of the manifestations in SLE is the involvement of the nervous system, which 
includes a diversity of neurological and psychiatric events. Around 39-50% of SLE 
patients are presenting NPSLE symptoms [61]. There is a difference in NPSLE 
manifestation attributed to SLE compared to neurological manifestations as a 
complication of the disease or due the treatment of the SLE. The American College 
of Rheumatology (ACR) established in 1999 criteria which the clinicians use for the 
diagnosis of NPSLE [62]. In these criteria clinicians can segregate the NPSLE in 
diffuse and focal NPSLE.
Patients with NPSLE are treated in many different ways, due to the different types of 
disease and inflammation, also the type of symptoms in NPSLE play an important 
role in the type of treatment [63].
Complement factors are known to contribute to the pathology of inflammatory central 
nervous system (CNS) and neurodegenerative diseases [64]. In cerebrospinal 
fluid (CSF) an increase of complement components C3, C4 and C5b9 were found 
[65, 66]. This may impact on disease progression as in mice that were deficient 
for alternative complement pathway activity, less lupus cerebritis was seen as 
compared to controls [67].
Recently, research groups demonstrated that activated microglia are important 
producers of complement components, which can be of importance in inflammatory 
conditions in the brain like depression, but also in NPSLE [68]. 
Furthermore, the breakdown of the blood brain barrier (BBB) is prominent in NPSLE 
as well as the presence of autoantibodies against brain antigens like glutamate 
receptors. These antibodies against glutamate receptors are known to play an 
important role in neurodegenerative diseases [69-71]. Also autoantibodies against 
complement components could play a role in NPSLE, but the exact mechanism is 
still unknown.
The role of complement in arthritis
There is strong evidence that complement plays an important role in the pathogenesis 
of rheumatoid arthritis (RA) and osteoarthritis (OA) [72]. One study in 2013 showed 
that single nucleotide polymorphisms (SNPs) in and around the C1q genes were 
associated with the susceptibility of RA. These results could be explained because 
the genetic variants would increase the production of C1q leading to an increased 
capacity to activate the classical pathway [73], and suggest that more complement 
activation associates with more joint damage. As seen in several studies, a 
decreased haemolytic activity and complement components was found in the 
synovial fluid, indicating local complement activation and consumption [74-76]. In 
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mouse models of inflammatory arthritis it was found that complement activation is 
involved in joint damage especially complement component C5a [77]. 
One of the factors activating the classical pathway is binding of C1q to immune 
complexes and to microparticles from apoptotic granulocytes, where deposition 
of C1, C3 and C4 was seen in synovial fluid [78]. The alternative pathway has 
been suggested to be more involved in the complement activation in the joint 
for there was an increase Bb fragments found in RA synovial fluid [79] and in 
rodent arthritis models it is demonstrated that factor B or C5 deficient mice were 
protected from arthritis whereas C4 deficient mice not [80, 81]. Cartilage fragments 
are recently implicated as complement regulators. Several studies indicate that 
several components of the extracellular matrix (ECM) are enhancing and others are 
inhibiting complement activation [82-84]. 












C1q gene and protein
The genes C1QA, C1QB and C1QC are located on the p-arm of chromosome 1 
(chromosomal location: 1p34-1p36.3). These genes encode for the constituents 
of the C1q molecule, the C1q A, B and C peptide chains that each form one 
helical strand and all contain a short N-terminal region, a collagen-like region and 
a C-terminal globular region (gC1q domain) (Figure 1). The collagen-like regions 
assemble into helical conformations. Six of these structural triple helix units form, 
because of non-covalent interactions via two C-chains, the hexameric C1q molecule 
that has an overall structure that resembles a bouquet of tulips [85] or an ‘Eiffel-
tower’-like structure [86]. Structurally the C1q molecule (460 kDa) is composed of 




In contrast to most other complement factors, C1q is not produced by hepatocytes 
but mainly by macrophages and immature dendritic cells [9, 10]. Following their 
maturation, dendritic cells completely shut down C1q production [9, 10] suggesting 
a role for C1q in adaptive immune responses [4, 7]. Indeed, a role for C1q in 
adaptive immunity can also be concluded from in-vivo studies regarding antigen 
presentation [87], cellular activation of immune cells [88, 89] and setting a tolerance 
threshold [90-92]. 
C1q binding to immunoglobulins; monomeric versus hexameric
C1 driven complement activation can be triggered via the binding of C1q to the 
Fc-region of IgM or IgG and activation of C1r-C1s tetramer [93]. For IgM, the most 
efficient activation is associated with the hexameric form, representing a minor 
fraction of total IgM (5% of total IgM) [94]. Hexameric IgM (IgMh) differs from 
pentameric IgM (IgMp) in the absence of J-chain, which is an evolutionary conserved 
peptide that covalently links pentameric IgM and functions to its transepithelial 
transport by binding the poly-Ig receptor. The lack of J-chain in IgMh possibly 
represents a mechanism to prevent polymeric Ig, with high complement activation 
potential (approximately one-log compared to IgMp, [95], to be transported to the 
mucosal surfaces where the antigenic load is generally high [96]. The physiological 
function of human IgMh is still largely unknown.  Melis et al. propose that IgMp and 
IgMh should be seen as two distinct subclasses [97] and not as a side product of 
evolution.
The C1q binding sites are hidden in IgMp, but are forced outwards by a star-to-
staple conformational change upon antigen binding [98-100] and at the same 
time the complex glycans are turned inside. These conformational changes may 
decrease the clearance rate of IgMp and initiate complement activation after 
binding of C1q [101, 102]. The hexameric form, on the other hand, appears to be 
a planar molecule in which all of the variable regions are available for antigen and 
Fc-binding [101, 103]. 
The binding of one of the C1q head domains to an IgG-Fc part is of low affinity 
[104, 105]. Activation of the classical pathway by IgG requires that at least two IgG 
molecules bind to C1q (at least for non-nucleated cells). Only in rare cases certain 
paraproteins have been reported to induce C1 activation while in monomeric form 
[106]. Attachment of IgG to antigens in close proximity to each other, allows C1q 
to bind more than one Fc-region, thereby activating complement [98, 107]. Simple 
proximity binding however appears to be insufficient for maximal complement 
activation by IgG. Diebolder et al. recently demonstrated that IgG molecules form 
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ordered hexameric structures after they bind cell surface-expressed antigen. These 
hexamers form a docking station for C1 binding and activation. Mutations that 
interrupted hexamer formation led to strongly decreased C1q binding and CDC. All 
features to potentiate levels of complement activation described above, together 
with the structural data for C1q, IgG and IgM hexamers therefore fit with the notion 
that Ig hexamerization is required for potent activation of the classical pathway of 
complement [86, 108].
Figure 3. Schematic overview of the interactions between C1q and immunoglobulins
A. In fluid-phase; C1q avidity too low for binding to monomeric IgG molecules under physiological 
conditions and therefore no activation. B. Antibody binding to antigens allows hexamerisation via Fc-Fc 
interactions, this generates an optimal platform for C1q binding and activation. C. Anti-C1q autoantibodies 
do not bind to fluid-phase C1q and are therefore non-depleting. D. Anti-C1q autoantibodies bind to 
solid-phase C1q and amplify complement activation [109]. 
A. Fluid phase IgG binding B. Solid phase IgG binding
C. Fluid phase anti-C1q binding D. Solid phase anti-C1q binding
IgG monomers
“Low avidity” binding High avidity binding
IgG hexamer formation
No binding
anti-C1q autoantibodies anti-C1q autoantibodies
Binding
Figure 2
C1q traditional and non-traditional roles  
The traditional view on the role of C1q is restricted to the activation of the classical 
pathway following its binding to ligand bound IgM or multimeric IgG [110]. The list 
of ligands for C1q has grown considerably, now also including DNA [111], CRP 
[112], and matrix molecules such as decorin [83, 113, 114]. 
In the observation regarding the accumulation of apoptotic cells received a lot 
of attention. Normally apoptotic cells are hardly detectable in tissues as these 
are rapidly eliminated by e.g. macrophages. Hence the “waste disposal” theory 
was introduced suggesting that C1q, by binding to dying and dead cells would 
stimulate phagocytosis [115]. Indeed dedicated in-vitro experiments revealed that 
early, and especially late apoptotic cells could bind C1q [116, 117], which resulted 
in more efficient uptake by phagocytes [118, 119]. The uptake of C1q-opsonized 
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apoptotic cells by phagocytes not only clears a potential source of autoantigens 
but also impacts on the immune status of the phagocyte [120]. The complement 
activation that occurs as a result of C1q binding to dead cells needs to be well 
controlled to allow for efficient opsonisation, including C3b fragments, without the 
risk of lysis and release of autoantigens [121, 122]. Next to C1q, apoptotic and 
necrotic cells were also shown to bind MBL [123] and properdin [124] to enhance 
complement mediated opsonisation. The process of apoptotic cell clearance 
is essential in physiology and is characterized by redundancy. Therefore it was 
postulated that C1q may instead, or additionally, impact on the threshold for auto-
reactivity in the adaptive immune response. Indeed both in-vitro studies and studies 
in C1q-deficient mice indicate that C1q impacts on the adaptive immune response 
[87, 90-92, 125]. 
Apart from the effects of C1q as part of the complement activation cascade 
described above, several reports have implicated C1q in processes that may not per 
se involve additional complement activation. For example C1q has been reported to 
play an important role in nerve pruning [126] Wnt/Beta-catenin signalling [127, 128]. 
Also a role for C1q was reported on neoangiogenesis [129]. C1q could potentially 
exert such effects in the absence of complement activation by the activation of 
cellular C1q receptors. Over the years several receptors have been considered 
to be C1q receptors and several have since then been abandoned. The gC1q-
Receptor and the cC1q-Receptor are still considered bonafide C1q receptors [130] 
and additionally a role for C1q binding to the inhibitory collagen receptor LAIR-1 
was reported [131]. 
Genetic C1q deficiency
Genetic deficiency of C1q is strongly associated with development of Systemic 
Lupus Erythematosus (SLE) [132]. This observation defined the lupus-paradox, 
where in most SLE patients C1q contributes to tissue damage by inducing 
complement activation via tissue-deposited immune complexes (ICs), whereas 
genetic deficiency of C1q is also associated with development of SLE [133]. Clearly 
C1q is not essential for the clinical presentation of SLE, but how C1q contributes 
to the protection against the development of SLE remains to be solved. A major 
breakthrough was achieved when the first C1q knock-out mice were generated 
[134]. These mice developed a lupus-like disease and importantly the investigators 
observed increased numbers of apoptotic cells [134]. Later it was shown that the 
lupus-like disease observed in these first C1q-deficient mice was largely due to the 
breeding strategy in which a large genetic segment containing autoimmunity-prone 
genes was co-transferred [135]. Next to a variety of papers describing the effects 
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of complete genetic deficiency of C1q, several reports that describe associations 
between SNPs in C1q and clinical phenotypes have appeared. The presence 
of SNPs in the C1q genes has been associated with differences in response to 
rituximab treatment for lymphoma treatment [136, 137] as well as with development 
of SLE [138-143] or development of RA [73].
Antibodies against the C1 complex
Anti-C1q autoantibodies
The past four decades anti-C1q autoantibodies have been studied in a wide variety 
of autoimmune and renal conditions as well as in infectious diseases [144]. In the 
healthy population the prevalence of anti-C1q autoantibodies ranges between 
2% and 8% [106, 145-148] and increases with age [149]. Hypocomplementemic 
Urticarial Vasculitis Syndrome (HUVS) represents the clinical condition with 
the highest percentage of anti-C1q positivity; 100% [150]. Other conditions 
characterized by high anti-C1q antibody prevalence are, mixed connective tissue 
disease (94%), Felty’s syndrome (76%), and SLE (30–60%) [144, 146, 148, 151].
The occurrence of anti-C1q autoantibodies was shown to have familial clustering, 
indicating that there is a genetic risk factor that together with environmental cues 
may precipitate the production of these antibodies [152]. Anti-C1q autoantibodies 
have also been described to occur in infectious diseases although at a frequency 
of around, for example 13% of HIV infected individuals vs. 5% in healthy controls 
[153] or up to 26% in patients suffering from hepatitis C virus infection as compared 
to 10% of healthy controls [154].
Anti-C1q autoantibodies cannot be used as a diagnostic tool however, the presence 
of anti-C1q autoantibodies can provide prognostic information. This has been 
particularly instrumental in the renal complication of systemic lupus erythematosus 
(SLE), lupus nephritis (LN). Anti-C1q autoantibodies were reported to occur in 30–
60% of the SLE patients and to be especially present in those patients that among 
the many clinical presentations also suffered from LN [144, 155].
Several studies provide evidence that anti-C1q autoantibodies are superior to other 
serological markers in identifying a flare of LN [156, 157]. However, other studies 
indicate that combinations of anti-C1q antibodies with other serological markers 
are superior to anti-C1q antibodies alone [158-160]. Especially striking is the strong 
negative predictive value of anti-C1q testing for LN. In the absence of anti-C1q 
autoantibodies it is very unlikely that a patient with LN will develop a flare [106, 156, 
158, 161-163]. As many of these studies report on rather small patient populations 
from very diverse ethnic backgrounds ranging from Brazil [163], China [164], India 
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[165], and Egypt [166] it is likely that considerable variation exists in the strength 
at which anti-C1q antibodies are associated with and is predictive for LN flares. 
Several of the larger studies from Europe and Hong Kong point in the same direction 
[156, 159, 167] and also a recent meta-analysis confirmed the diagnostic value of 
serum anti-C1q antibodies for LN [168]. Whether or not anti-C1q antibodies are also 
associated with the disease activity of LN remains to be established, as currently 
there is no consensus on this issue [147, 159, 169]. Also in post-streptococcal 
nephritis anti-C1q autoantibodies were reported to associate with a worse outcome 
[170]. Collectively these data suggest that anti-C1q by itself may not be pathogenic 
to the kidney, as anti-C1q autoantibodies are also found in the healthy population. 
This would imply that only following a specific insult to the kidney these anti-C1q 
autoantibodies could enhance the local pathology, as seen in the enhanced LN 
in SLE and PSGN. Experimental evidence for a pathogenic contribution of anti-
C1q autoantibodies came from murine studies [171-174]. Administration of anti-
C1q antibodies to healthy mice results in a modest deposition of C1q and anti-
C1q antibodies but this does not induce renal impairment [172]. In sharp contrast 
anti- C1q autoantibodies strongly aggravate immunecomplex-mediated nephritis 
[173]. The mode of action was depending on the presence of C1q in the immune 
complexes in the glomeruli, as anti-C1q autoantibodies were not able to aggravate 
glomerulonephritis induced by non-C1q fixing immune complexes [173]. Anti-
C1q autoantibodies may also play pathogenic roles in other conditions such as 
autoimmune thyroid disease [148]. 
One mechanism to clear anti-C1q autoantibodies from the circulation is to use 
immunoabsorption on C1q-columns [175]. This method depleted next to circulating 
immune complexes also anti-C1q autoantibodies and was shown to be beneficial 
in SLE patients [176, 177].
Assays to detect anti-C1q
Over time several assays have been developed to detect anti-C1q autoantibodies 
both in humans and in experimental animal models. The first assays employed a 
direct coating of intact C1q, which necessitated the use of high salt conditions to 
discriminate between immune complex binding and anti-C1q autoantibody binding 
[178]. Already early in the history of anti-C1q autoantibodies it was discovered that 
the majority of these autoantibodies is directed against the collagen-like part of 
the C1q molecule [179]. From equilibrium studies and from the observation that 
anti-C1q antibodies can be found in the presence of freely circulating C1q it was 
argued that anti-C1q antibodies may interact with epitopes that are not exposed in 
C1q in fluid phase [180]. Later these arguments were supported by elegant studies 
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Table 1.  History of anti-C1q antibodies
Year Milestone
1971/88 Identification of C1q as the target of autoantibodies [179, 185]
1982 C1q in solid phase exposes neo-epitopes [180]
1984 Identification of the collagen-like stalk as the main binding site 
of anti-C1q antibodies
[186, 187]
1987 Anti-C1q associates with the occurrence of LN [188]reviewed a.o. 
[144]
1991 Identification of anti-C1q in mice [122]
1996 Anti-C1q also present in healthy population and increase with 
age
[171]
1993 Anti-C1q also present in healthy population and increase with 
age
[149]
2004 Experimental evidence on how anti-C1q can be pathogenic to 
the kidney in LN but not in healthy individuals
[173]
2007 Identification of anti-C1q antibodies that target the globular 
heads
[183]
using phage display technology generated Fab fragments that only interacted with 
solid-phase C1q [181]. Next, assays have been developed that utilized only the 
C1q collagen-like region, generated by enzymatic digestions as antigen [145, 179]. 
This eliminated the need to use high ionic strength buffer. A recent paper reports 
on the use of peptides derived from C1q that have interesting properties to detect 
a major linear epitope in a high percentage of the patients in the absence of high-
ionic strength buffer [182]. In contrast to the assays reported before that anti-C1q 
antibodies only target the collagen-like region of C1q in 2007 it was discovered that 
there are also antibodies that specifically target the globular head regions of C1q 
[183]. 
To study anti-C1q antibodies in experimental animal models, assays were developed 
that used coating of purified mouse C1q and high salt conditions similar to the 
human situation [171, 172]. Next, in order to circumvent the purification of mouse 
C1q, an assay was developed which employed a coating of C1q binding peptides, 
that captured C1q from Rag-/- serum, as the antigenic entity for the anti-C1q ELISA 




Autoantibodies targeting C1s have been described to occur in around 50% of the 
SLE patients [184]. The binding of these autoantibodies to C1s enhances its activity 
and has been suggested to be partially responsible for the reduced levels of C4 
observed in SLE [184]. As these antibodies have only been described in one study, 
future studies will have to reveal the clinical implications of the presence of these 
antibodies.
Scope of the thesis
The scope of this thesis is to describe several aspects of the role of C1q in immunity 
and autoimmunity in a clinical- and cellular perspective. 
The clinical association of C1q and anti-C1q in autoimmunity
C1q deficiencies are relatively rare, but have a strong association in the development 
of SLE. Around 80% of the C1q deficient patients will develop SLE, but the clinical 
outcome is variable. In chapter 2, we describe a Dutch child with C1q deficiency 
presenting only recurrent infections without any signs of autoimmunity.  This made 
us curious about other C1q deficient patients and their clinical outcome. In chapter 
3, we investigated the variability in clinical presentation and outcome of C1q 
deficient patients worldwide using questionnaires. Some C1q deficient patients with 
SLE are diagnosed with a genetic mutation resulting in the production of low levels 
of C1q that has a low molecular weight (LMW-C1q). In chapter 4, we describe 
a C1q deficient patient producing low levels of C1q with a low molecular weight 
who is diagnosed with SLE and NPSLE. The role of complement activation and 
NPSLE is not well known. The studies presented in chapter 5, describes if there is 
an association between complement activation and anti-C1q antibodies in patients 
with NPSLE. 
Local Production of C1q by immune and non-immune cells
As described by several groups the main producers of C1q are immature dendritic 
cells and macrophages. Because both cells are from myeloid origin we focused 
on another cells originating from the same progenitor. In chapter 6, we describe 
the production of C1q in mast cells, indicating that mast cells can contribute to 
complement activation in tissue where mast cells are predominantly present like 
the skin or synovial tissue. In chapter 7, we discuss the role of C1q produced by 
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Abstract
C1q deficiency is a rare genetic disorder that is strongly associated with development 
of Systemic Lupus Erythematosus (SLE). Several mutations in the coding regions 
of the C1q genes have been described that result in stop-codons or other genetic 
abnormalities ultimately leading to C1q deficiency. Here we report on a Dutch boy 
suffering from recurrent infections with a complete C1q deficiency, without any SLE 
symptoms.
The presence of C1q in serum was assessed using ELISA and hemolytic assay. By 
western blot we examined the different C1q chains in cell lysates. We identified the 
mutation using deep-sequencing. By qPCR we studied the mRNA expression of 
C1qA, C1qB and C1qC in the PBMCs of the patient.
Deep-sequencing revealed a homozygous mutation in the non-coding region of 
C1qB in the patient, whereas both parents were heterozygous. The mutation is 
located two nucleotides before the splice site of the second exon. In-silico analyses 
predict a complete abrogation of this natural splice site. Analyses of in vitro cultured 
cells from the patient revealed a lack of production of C1q and intracellular absence 
of C1qB in the presence of C1qA and C1qC peptides. Quantitative PCR analysis 
revealed total absence of C1qB mRNA, a reduced level of C1qA mRNA and normal 
levels of C1qC mRNA.
In this study we report a new mutation in the non-coding region of C1qB that is 
associated with C1q deficiency.
Introduction
C1q is the recognition molecule of the classical pathway of complement activation 
[1]. Next to its role in activation of the complement system, C1q has also been 
shown to bind to apoptotic and necrotic cells to facilitate their clearance [2, 3]. In 
the absence of C1q, accumulation of apoptotic material was noted, which led to 
the formulation of the ‘waste disposal hypothesis’[4, 5]. Likewise, in the absence 
of C1q also immune complexes cannot be cleared effectively resulting in their 
accumulation. Over the recent years more insight has been generated in the role 
of C1q in modulating the adaptive immune response [6-8]. Collectively these data 
indicate that absence of C1q may not only impact on clearance mechanisms for e.g. 
apoptotic cells and immune complexes, but also on the adaptive immune responses 
[9]. In most C1q deficient individuals the balance is shifted towards autoimmunity 
and the development of Systemic Lupus Erythematosus (SLE). Complete genetic 
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deficiency of C1q is strongly associated with development of SLE, but in some 
individuals the disease mainly presents with recurrent infections or, in exceptional 
cases, remains largely unnoticed [10-12].
The C1 complex is composed of 3 different proteins; one C1q molecule, two C1r 
molecules and two C1s molecules. C1q is the recognition molecule of the C1 
complex and is composed of 18 polypeptide chains: 6 C1qA, 6 C1qB and 6 C1qC. 
Each chain has a collagen-like region (N-terminal region) and a globular head 
region. The C1qA chains associate with the C1qB chains as heterodimers. C1qC 
chains first will form homodimers and finally associate with the A-B heterodimers to 
eventually form a tulip-like structure [13]. The genes encoding these three subunits 
are located on chromosome 1 within a genomic region of ~25kb and have an 
ACB orientation [14]. C1q is thought to be produced predominantly by immature 
dendritic cells and macrophages [15, 16]. C1q production can be upregulated via 
IFN-γ stimulation in which the expression of the three chains is suggested to be 
synchronized via transcription factors PU.1 and IRF8 [17]. 
Nowadays around 65 cases of C1q deficiencies have been reported [18]. These 
deficiencies are mostly caused by homozygous mutations in one of the chains. The 
most common mutation is in the A-chain caused by a nonsense mutation whereby 
a transition of C to T occurs in a codon for Glu-186 [13]. Next to mutations causing 
C1q deficiency also several genetic variations in C1q have been associated with 
increased risk for developing autoimmunity [19, 20]. To which extent mutations in 
different C1q chains affect the clinical presentation, e.g. infection versus SLE, is 
currently unclear. 
Here we report on a non-coding homozygous mutation in an RNA splice site that 
leads to complete lack of expression of C1qB and hence lack of secretion of C1q. 
Materials and Methods
Patient and controls
We have analyzed in detail one C1q-deficient Caucasian patient and studied 
materials obtained from both his parents as controls as well as a reference panel 
of 48 healthy adult controls collected in the LUMC. Informed consent was obtained 
from the parents and the controls in compliance with the Helsinki declaration.
Samples
Blood was collected from the patient and both parents in order to obtain serum and 
to isolate DNA. From the patient also PBMCs were collected using Ficoll-Paque 
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density gradient centrifugation. Control serum samples were chosen matched by 
age of the parents.
Functional reconstitution complement activity assays
Using an erythrocyte lysis assay the complement-mediated hemolytic activity was 
measured. Rabbit antibody coated sheep erythrocytes were used and different 
dilutions of serum of the patient or normal human sera (NHS) were added to C1q-, 
C2- or C4-depleted serum. Hemolysis was assessed by measuring OD at 414 nm, 
and specific complement-mediated lysis was calculated as described before [21].
To exclude the possibility that next to C1q deficient the patients sample would 
also be deficient for C1r or C1s we performed assays to measure activation of 
the classical pathway of the patient serum by reconstitution of purified C1q. Plates 
coated with human IgG were incubated with 1% serum of the patient (diluted in 
GVB++; 0.1 % gelatin, 5 mM Veronal, 145 mM NaCl, 0.025 % NaN3, 0.15 mM 
calcium chloride, 0.5 mM magnesium chloride, pH 7.3) with or without addition of 
purified C1q (Quidel) in different concentrations. As a read-out C4 deposition was 
measured. 
Cell stimulation 
PBMCs (1 x 106 cells/ml) were stimulated in a 48 wells plate (Corning Inc.) for 
72 hours using RPMI (Gibco) supplemented with IFN-γ (200 U/ml, Peprotech) and 
10 µM dexamethasone (Pharmacy LUMC, Leiden, The Netherlands) as described 
before to increase the C1q secretion (Walker, 1998;Moosig et al., 2006;Kaul & 
Loos, 2001). After 72 hours the supernatants and the cells were collected. The 
supernatants were used for ELISA and the cells for extraction of mRNA for qPCR 
and for western blot analysis of cell lysates.
Detection of C1q by ELISA 
C1q levels in serum and culture supernatants were analyzed by ELISA. Maxisorp 
plates (Nunc) were coated with rabbit anti-human C1q (DAKO) in coating buffer 
(0.1 M NA2CO3, 0.1 M NaHCO3, pH 9.6) overnight at 4°C. Plates were washed 
in PBS/0.05% Tween (PBS-T, Sigma). Then the wells were blocked with PBS/1% 
BSA for 1 hour at room temperature. After washing, the standard of C1q (Quidel), 
applied in a two-fold dilution series starting from 150 ng/ml, control samples and 
patient samples in a 1:8000 dilution in PBS/1% BSA/0.05% Tween (Sigma) were 
added to the wells. The standard and the serum samples were incubated for 1 
hour at 37°C. After incubation the plates were washed and rabbit anti-C1q DIG 
(Nephrology, LUMC) was added to the wells and the plate was incubated for 1 
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hour at 37°C. As detection antibody sheep anti-DIG HRP (Roche diagnostics) 
was added for 1 hour at 37°C, following final washing a substrate reaction was 
performed using ABTS (Sigma). C1q levels in the cell supernatants were measured 
with minor adjustments.
Detection of C1q by western blot
The presence of C1q in serum and in lysates of cultured PBMCs was analyzed 
by western blot. Serum samples of the patient and his parents were analyzed 
using reducing conditions at a dilution of 1:100 of the samples. Cell lysates were 
generated from PBMCs after 72 hours of stimulation. Cells were lysed on ice in 
lysis buffer (Roche Diagnostics) supplemented with a protease inhibitor (Sigma) 
for 30 minutes on ice. To avoid contamination of cell debris, cell lysates were 
centrifuged. The cell lysates were diluted 4x with Laemmli sample buffer (Bio-Rad)/ 
5% ß-mercaptoethanol (Merck) and boiled for 5 minutes on 95°C to reduce the 
samples. Proteins were separated by SDS/PAGE on a mini-protean TGX precast 
gel (4-15%, Bio-Rad) followed by protein transfer on a Trans-Blot Turbo Transfer 
pack: mini, 0.2 µM PVDF (Bio-Rad). The membrane was blocked one hour in PBS 
containing 0.05% Tween and 3% skimmed milk (Fluka) on room temperature. Next, 
the blot was incubated with rabbit anti-human C1q (DAKO) overnight on 4°C. After 
washing with PBS/0.1% Tween the membrane was incubated with goat anti-rabbit 
HRP (DAKO) for 1 hour at room temperature. Then the blot was washed and C1q 
was visualized using ECL Western Blotting Analysis system (GE Healthcare). 
 
Sequencing
Genomic DNA was extracted from blood collected with tubes supplemented with 
EDTA. Sequencing of the complete C1q genes (C1qA, C1qB and C1qC), of both 
introns and exons was performed. Deep-sequencing was performed using the 454 
NGS Roche GS FLX Titanium platform. Data were compared to internal controls and 
to Human Genome build 19 as well as Human_v37_2 de dbSNP database v132 
using the NextGENe software package for Next Generation Sequence Analysis 
(NGS) from Softgenetics. The effect of the mutation on splicing was in-silico analyzed 
using the NetGene2 Server http://www.cbs.dtu.dk/services/NetGene2/. To confirm 
the mutation Sanger sequencing was performed on C1qB using standard protocol. 
qPCR
RNA was isolated from the cultured cells using the mirVana RNA isolation kit (Life 
Technologies) and analyzed with the NanoDrop (NanoDrop Technologies), followed 
by DNase treatment (Invitrogen) and cDNA synthesis with superscript III (200U/µl, 
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Invitrogen). Real time SYBR Green I qPCR was performed with primers specific 
for C1q genes C1qA/B/C separately (see table 1 for primer sequences) to analyze 
expression on transcriptional level. ß-actin was used as reference gene, CD14 
gene expression was used as control for cellular input. The cDNA was diluted 1:50 
and qPCR was performed using SensiFast Sybr (Bio-line) and primers with a start 
concentration of 10 pmol. The qPCR was performed on the real time PCR system 
(BioRad CFX-384) with an activation step of 3 min on 95°C (hot start polymerase 
activation), a melting temperature of 95°C for 5 seconds and an annealing 
temperature of 60.5 °C for 5 seconds and an elongation step for 20 seconds on 
72°C for 40 cycles. At the end of the protocol melting curves were performed from 
65°C to 95°C  to test specific binding of SensiFast Sybr. The qPCR products were 
analyzed on a 2% agarose gel and visualized with nancy 520 (Sigma).
Statistical analysis
Statistical analysis on the qPCR data was performed  using paired sample t-test. 




Here we describe a Dutch boy born from two Caucasian, healthy, non-
consanguineous parents. During the first years of life he has suffered from recurrent 
upper airway infections. At the age of three he developed redness and swelling 
of the left ankle combined with fever (39°C) after an injury. Initially a cellulitis was 
suspected and treated with flucloxacillin. Due to persistent complaints he was 
admitted to a local hospital. A subsequent skeletal scintigraphy yielded a hotspot of 
the distal tibia compatible with the diagnosis osteomyelitis. Blood cultures remained 
negative. After intravenous antibiotics he recovered completely.
Gene 5’ Forward 3’ Reverse
ß-actin GCAATGAGCGGTTCCGCTGC CGATCCACACGGAGTACTTG
C1qA exon 3 TGGAGTTGACAACAGGAGGC CGATATGGCCAGCACACAGA
C1qB exon 1 - 2 GACCGAGGGCAGTAGGCTC TCATCATACTGTGTCAGACGCC
C1qC exon 2 - 3 AAGGARGGGTACGACGGACT GTAAGCCGGGTTCTCCCTTC
CD14 GCCGCTGTGTAGGAAAGAAG AGGTTCGGAGAAGTTGCAGA
Table 1.  Primers used in the qPCR analysis
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At the age of 5, he was admitted due to seizures and high fever. The analysis 
of cerebrospinal fluid yielded 470 x10E6 leukocytes/liter and both blood and CSF 
cultures showed a pneumococcal infection. Treatment with cephalosporin and 
dexamethasone resulted in complete recovery.
Examination of his medical history revealed that he had frequent upper airway 
infections and analysis for immune deficiencies showed a low classical pathway 
activity of 2% (reference range > 74 %) and a low level of IgG4 (0.007 g/l) (reference 
range 0.017 – 1.58 g/l), whereas C3 (1.1 mg/L, reference range: 0.9-2.0mg/L) 
and C4 (267 mg/L, reference range: 95-415 mg/L) were in the normal range. The 
alternative pathway (74%, reference range: >39%) showed no abnormalities and 
no antinuclear antibodies and rheumatoid factor were detected. Using an activity 
assay we investigated which complement protein from the classical pathway was 
defective. Complete absence of functional complement protein C1q was detected 
by reconstitution experiments in a C1q-specific hemolytic assay (Figure 1A). 
Similar reconstitution experiments revealed that the patient has a normal C2 and 
C4 activity (Figure 1B-C). With a reconstitution assay we could rescue the activity of 
the classical pathway by adding purified C1q to the patient serum (Figure 1D). At 
follow-up at the age of 8 years he was healthy without infectious problems or signs 
of autoimmunity. 
Complete absence of C1q in the serum 
Using ELISA we confirmed a complete C1q deficiency in the patient. Sera of both 
parents were also analyzed and their level of circulating C1q was in the same range 
as values obtained in a set of healthy adult controls (Figure 2A). In addition we have 
used western blot to analyze the presence of C1q in sera of the patient, parents 
and controls, which also confirmed the complete absence of circulating C1q in the 
patient, with normal levels in the parents (Figure 2B). 
Identification of a splice site mutation in C1qB 
Deep sequencing of the C1q genes (C1qA,B,C), revealed a mutation  in homozygous 
state  in the patient and in heterozygous state in both parents (data not shown). 
This mutation is located 2 nucleotides before the mRNA splice site of the second 
exon of C1qB (g.6251A>C). In-silico prediction programs indicate a complete 
absence of splicing when the mutant form is present. As a confirmation also Sanger 
sequencing was performed on the C1qB region identified by deep-sequencing. 
Using this technology, it was confirmed that the patient has a nucleotide change 
replacing adenine into a cytosine (Figure 3).
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Figure 2. ELISA  and western blot analysis of patient serum. 
A. The presence of C1q in the serum was analyzed by ELISA. Diluted serum from the C1q-deficient 
patient (C1q def pt), mother and father (M + F) were compared with healthy controls (n=48) (Ctr). Dashed 
horizontal line indicates the lower detection limit of the assay, which was 0.01 µg/ml. B. Serum samples 
from the C1q-deficient patient together with the mother and father were analyzed by western blotting for 
the presence of the peptides C1qA, C1qB and C1qC in the serum using an antibody staining for C1q. 
A B
Figure 1. Functional reconstitution complement activity assays. 
A. The addition of patient serum or NHS in a dilution range to C1q depleted serum. The total lysis is used 
as read-out. As positive control (100% lysis) distilled water was used. B. The addition of patient or NHS 
to C2 depleted serum. C. The addition of patient or NHS to C4 depleted serum. D. Reconstitution of the 
classical pathway by adding 0.05 µg/ml, 0.5 µg/ml and 2.5 µg/ml purified C1q to the patient serum. As 
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Figure 3. DNA sequencing data from the C1q-deficient patient. 
A. Data obtained from deep sequencing showing a C1qB mutation on location chr1:22,985,930, g.6251A 
> C. B. As confirmation Sanger sequencing is performed indicating a nucleotide change in the intron 













No secretion of C1q by PBMCs of the patient in-vitro
With western blot we confirmed that C1q is present in serum from both parents 
whereas the child is completely C1q-deficient (Figure 2B). As absence of circulating 
C1q in serum could be the result of either lack of production or consumption, we 
studied the secretion and intracellular accumulation of C1q using cells of the patient 
and control. Analysis of culture supernatant from PBMC’s of the patient collected 
after 72 hours of stimulation with IFN-γ and dexamethasone revealed no secretion 
of C1q, whereas significant amounts of C1q were present in the supernatant of 
control PBMC in unstimulated and in the stimulated conditions (Figure 4A). Lack of 
secretion of C1q can be the result of intracellular accumulation of C1q. Therefore 
we also investigated the intracellular presence of C1q, using western blot analysis 
on cell lysates. Following 72 hours stimulation with IFN-γ and dexamethasone the 
three peptides of C1q were clearly detectable in the lysates of the control PBMC’s. 
However, in the lysates of PBMC’s of the patient only expression of C1qA and C1qC 
was detected, but no C1qB peptide (Figure 4B). Taken together, the results show 
that C1qA and C1qC peptides are transcribed and translated and that the C1q 
deficiency is due to the absence of the C1qB peptide.
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Figure 5. Expression levels of C1qA, C1qB and C1qC
A. Relative mRNA expression of the three C1q chains after stimulation with IFN-γ and DXM for 72 hours. 
As reference gene ß-actin was used. **P < 0.01, *** P < 0.001. B. qPCR products from control PBMCs 














Figure 4. ELISA and western blot of stimulated cells from the C1q-deficient patient. 
A. Undiluted cell supernatants were analyzed in duplicate by ELISA for the presence of C1q with or 
without stimulation of PBMC by IFN-γ (200 U/ml) together with DXM (10 µM).  PBMCs of the C1q-deficient 
patient were stimulated for 72 hour to increase the C1q production. PBMCs from a healthy person were 
used as a control. B. After stimulation, the presence of intracellular C1qA, C1qB and C1qC peptides 
were examined in reduced cell lysates. The three peptides were detected closely together: C1qA at 27.5 
kDa, C1qB at 25.2 kDa and C1qC at 23.8 kDa. 
qPCR analysis of expression of C1qA, C1qB and C1qC
A set of intron spanning primers was designed (Table 1) to analyze the expression 
levels of C1qA, C1qB and C1qC relative to the expression of the reference gene 
ß-actin. RNA isolated from the in-vitro stimulated PBMCs of patient and control was 
used as input material. We observed, as expected, complete lack of expression 
of C1qB in the patient (Figure 5), but also a partial reduction in the expression of 
C1qA by qPCR. The expression level of C1qC was not different between patient 
and control (Figure 5A). With the agarose gel we confirm that the primers for the 
qPCR are specific (Figure 5B). Expression levels of CD14, as a control for the input 
of monocytes, were similar in both control and patient (data not shown).
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Discussion
C1q deficiency is a rare hereditary condition associated with a high prevalence of 
SLE. The combination of reduced clearance of dying cells and immune complexes 
and an altered balance in the adaptive immune system likely increases the chance 
to develop the autoimmune disease SLE [7, 22, 23]. Globally around 65 patients 
have been described with a C1q deficiency [10]. Interestingly these patients 
display substantial variation in their clinical presentation, disease progression and 
outcome [24].
The patient described in this manuscript showed a clear absence of circulating C1q, 
but is not suffering from lupus, as evidenced by a lack of antinuclear antibodies 
and rheumatoid factor, but rather from recurrent infections. Although the patient is 
currently not suffering from lupus, the patient may develop lupus in the future. The 
IgG4 levels were lower compared to normal levels in this age category. This is often 
observed in patients with a complement deficiency in the classical pathway and 
may correspond with the recurrent infections of the upper airways [25].
A common phenomenon in C1q deficiency is that the parents are consanguineous, 
but the parents of this patient reported not to be related to each other (although not 
confirmed by genetic analyses). In the vast majority of C1q-deficient patients the 
mutation is located in the coding region of one of the chains, with only one report 
on a non-coding mutation   [10, 26]. The current patient also harbors a mutation in a 
non-coding region. The mutation, located in C1qB, results in the abolition of a splice 
site with as a consequence complete C1q deficiency. This splice site in intron 1 in 
front of exon 2, which influences the splicing of intron 1. Intron 1 has a size of 6kb, 
which is too large to be quantified by qPCR and therefore the product of C1qB will 
conceivably be too large for efficient transcription or an unstable protein will be 
translated. By qPCR the C1qA and C1qC chains are still detected. This suggests 
that in the absence of C1qB the transcription of C1qA and C1qC will remain. 
By western blot we could not detect any peptide of C1q in serum, but in cell lysates 
of activated PBMC’s, C1qA and C1qC chains, but not C1qB chains could be 
detected. The protein levels for the C1qA and C1qC chains were lower compared 
to the control. Because the C1qB chain is not produced, a complete C1q protein 
cannot be generated, possibly followed by degradation of C1qA and C1qC. This is 
confirmed by ELISA, where no secreted C1q could be detected after stimulation of 
PBMCs of the patient. 
In conclusion, we have identified a novel non-coding mutation in a splice site for 
C1qB that is associated with complete C1q deficiency. The patient showed several 
infectious problems but is currently doing well and shows no signs of autoimmunity. 
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He is receiving prophylactic antibiotics to protect him from severe infections and 
will stay under close control to detect possible development of autoimmunity in an 
early stage.
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Marked variability in clinical 
presentation and outcome 
of patients with C1q 
immunodeficiency
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Abstract
Globally approximately 60 cases of C1q deficiency have been described with a 
high prevalence of Systemic Lupus Erythematosus (SLE). So far treatment has 
been guided by the clinical presentation rather than the underlying C1q deficiency. 
Recently, it was shown that C1q production can be restored by allogeneic 
haematopoietic stem cell transplantation. Current literature lacks information on 
disease progression and quality of life of C1q deficient persons which is of major 
importance to guide clinicians taking care of patients with this rare disease.
We performed an international survey, of clinicians treating C1q deficient patients. 
A high response rate of >70% of the contacted clinicians yielded information on 45 
patients with C1q deficiency of which 25 are published.
Follow-up data of 45 patients from 31 families was obtained for a median of 11 
years after diagnosis. Of these patients 36 (80%) suffer from SLE, of which 16 suffer 
from SLE and infections, 5 (11%) suffer from infections only and 4 (9%) have no 
symptoms. In total 9 (20%) of the C1q deficient individuals had died. All except for 
one died before the age of 20 years. Estimated survival times suggest 20% case-
fatality before the age of 20, and at least 50% of patients are expected to reach their 
middle ages. 
Here we report the largest phenotypic data set on C1q deficiency to date, revealing 
high variance; with high mortality but also a subset of patients with an excellent 
prognosis. Management of C1q deficiency requires a personalized approach. 
Introduction
C1q deficiency is a rare hereditary disorder, which is strongly associated with 
development of Systemic Lupus Erythematosus (SLE)[1, 2]. The first C1q deficient 
patient was reported in 1979 [3]. To date more than 60 cases of C1q deficiency have 
been published with various mutations [4-8]. C1q deficiency has been observed in 
persons from several ethnic backgrounds [1].
C1q is the recognition molecule of the classical pathway of the complement system 
and together with C1r and C1s it forms the C1 complex. This complex is important 
for recognizing e.g. immune complexes and to activate the complement system. 
C1q is mainly produced by macrophages and immature dendritic cells and has 
several ligands including bound IgM, complexed IgG but also DNA and CRP [9-
11] In the context of autoimmunity another important ligand for C1q is present on 
apoptotic and necrotic cells [12-14]. Hence, C1q is important to clear necrotic 
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cells or apoptotic blebs from the circulation as described as the “waste disposal 
hypothesis” [15]. When the “waste disposal” is disturbed, apoptotic and necrotic 
material containing autoantigens accumulates resulting in a state that could 
predispose to development of autoimmunity like in SLE[16]. In addition to a role 
in the waste disposal process C1q has also been implicated in modulating the 
adaptive immune response[17-19]. Collectively these data indicate that absence 
of C1q may not only predispose to infections but also predispose to autoimmunity 
because of defective clearance of autoantigens and an altered adaptive immune 
response [20]. In most identified C1q deficient individuals the clinical presentation 
is towards autoimmunity and the development of SLE, whereas in some individuals 
the disease mainly presents in the form of recurrent infections e.g. meningitis and 
in exceptional cases remains largely unnoticed [5, 21].
Until now 16 nonsense and missense mutations have been described which  are 
present in 1 of the 3 chains of C1q  (chromosomal location: 1p34-1p36.3) [5, 22-25]. 
Mutations causing C1q deficiency are in most cases present in homozygous form 
and the parents often report a degree of consanguinity [5]. 
The treatment of C1q deficient patients has until recently mainly been aimed at the 
symptoms, rather than reversing the underlying C1q deficiency. The exception in 
the past has been the infusion of fresh frozen plasma containing C1q in a subset 
of the patients. This treatment has been well tolerated, led to substantial clinical 
improvements and did not lead to overt induction of anti-C1q antibody formation [23, 
26]. Based on the observation that C1q levels could be restored by bone marrow 
transplantation in C1q deficient mice [27, 28], now Haematopoietic Stem Cells 
Transplantations (HSCT) have been performed in  two C1q deficient individuals in 
Sweden and one in the United Kingdom. In all three cases the transplantation led to 
restoration of circulating C1q levels and an improvement in clinical symptoms [29-
31]. During follow-up two patients did well, whereas the other passed away due to 
intracerebral hemorrage and multi-organ failure. The risk of HSCT related morbidity 
and mortality has to be weighed against its potential benefits. HSCT related risk is 
increased in patients with advanced autoimmune disease, or organ damage caused 
by recurrent infections. Therefore, insight into the natural history of C1q deficiency 
is crucial to develop a therapeutic algorithm. Most current C1q deficiency literature 
reports on the identification of new mutations, in young children, but there is no 
data available on clinical follow up. In this study, we have conducted a survey by 
contacting clinicians who are currently treating C1q deficient patients. 
The aim of this study was to obtain insight into the prognosis of C1q deficient 
individuals. 
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The questionnaire:
• What is the age, gender and country of origin? 
• Are the parents consanguineous? 
• At which age was the C1q deficiency established? 
• Was the C1q deficiency confirmed by genetic tests? 
• What was the clinical diagnosis at the moment of establishing C1q deficiency 
(Infection/SLE/other)? 
• What was the age of first symptoms? 
• What were the first symptoms (Infection/SLE/other)? 
• What treatment options were applied and what was the response? 
• Were there any severe infections? Which type? 
• What is the frequency of mild infections? Otitis media / Upper respiratory tract in-
fections / Mild GI infections / Unexplained fever above 38°C (never / 1-2 x per year / 
3-5 x per year / > 5 times per year)? 
• Had there been any other significant clinical problems presentations after diagno-
sis? 
• Has the patient been successfully vaccinated? Has the patient received plasma, 
and was this successful?  
• Was stem cell transplantation considered? Why (not)? 
• Is the patient still alive? Yes (current age) No (age of death and cause of death)
• What is your impression of the overall quality of life of the patient (grade from 1-10 
with 1 being very poor and 10 being great)
• Please provide information of affected and unaffected relatives.
Table 1.The questionnaire that was sent to all clinicians treating C1q deficient patients
Methods
Questionnaire
To study the clinical follow up of C1q deficient individuals, we designed a 
questionnaire (Table 1). This was sent by email to the corresponding authors of 
several case- and concise reports as well as to clinicians treating C1q deficient 
patients. From the 45 individuals, 25 individuals are published in literature and 20 
are undescribed. 
Statistical analysis
The data from the completed questionnaires was analyzed using IBM SPSS 
Statistics Data Editor Version 20. The odds ratios are reported with 95% confidence 
interval and a p value. P-values <0.05 were considered significant. The differences 
between the quality of life in living patients and deceased patients were studied 
using a nonparametric t-test.
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We received completed questionnaires of 45 C1q deficient individuals from 31 
different families originating from 14 countries (Table 1). Although most of the cases 
were from countries in the Middle East, we also observed cases of native Dutch 
and Swedish origin. No sex bias was found for C1q deficiency (male 49% - female 
51%) or for SLE among the C1q deficient patients (male 42% - female 58%) (Table 
3). The median time from diagnosis to completion of the questionnaire was 6 years 
(range:0-34 years). The deficiency for C1q was mostly identified using hemolytic 
complement assays (CH50). In 60% of the described C1q deficient patients genetic 
analysis was also performed to identify the mutation associated with the C1q 
deficiency. Half of the patients have a mutation that has been previously reported in 
the literature. These mutations are most commonly in the C1qA and C1qC chains. 
Onset of disease
The median age at the time of the diagnosis of C1q deficiency was 9 years, but a 
wide age range from newborn until the sixth decade of life was observed (Figure 1). 
Most of the C1q deficiencies were identified as part of the routine work up for patients 
suffering from SLE or from unexplained recurrent infections. In the asymptomatic 
or less affected C1q deficient family members the diagnosis of C1q deficiency was 
often made during family screening. At the time of diagnosis 80% of the patients 
were suffering from SLE, 11% had only experienced recurrent infections and no 
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Table 3. Overview of the 
questionnaires about the 
C1q deficient individuals
SLE while 36% displayed SLE as well as recurrent infections. Cutaneous, discoid 
lupus was the most common presentation and related symptoms included a malar 
rash, oral ulcers, recurrent fever and vasculitis. SLE involving the central nervous 
system was found in one patient.  In our series 7% of the individuals, all male, were 
asymptomatic when C1q deficiency was diagnosed (Table 3). Overall 9 individuals 
(20%) died, all except for one before the age of 20 years (alive: N= 36, mean 20.0 
years ± 11.5 vs deceased: N = 9, mean 12.6 years ±11.7) (Figure 1). 
Among C1q deficient siblings one may present with SLE and/or infections, whereas 
the other is asymptomatic as previously observed in one Maroccan and one 
Turkish family [1, 25, 32]. In our series, one female from Sweden, one male from the 
Netherlands, and 4 affected brothers from the United Kingdom, presenting clinically 
with SLE and/or infections, had a C1q deficient brother that were completely 
asymptomatic at an age of 8 to 31 years. 
Infectious diseases
The first symptoms of disease reported for most C1q deficient patients were bacterial 
infections. The most common bacterial infections reported as first symptoms were 
recurrent otitis, meningitis, gingivostomatitis and urinary tract infection. In our 
questionnaire we asked the frequency of milder infections per year. We specifically 
asked for the more common mild infections such as otitis media, upper respiratory 
tract infections, mild gastrointestinal infections or unexplained fever (Figure 2). In 
11 patients (24%) these recurrent infections did not occur at all, whereas in 34 
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patients (76%) this was a frequent process typically involving multiple sites of 
infection. From this group thirteen patients had only suffered from mild infections 
(29%), three patients had only severe infections (7%) and eighteen patients that 
had both (40%).  Patients suffering from severe infections often also suffered more 
from milder infections (OR: 5.1, 95% CI: 1.2-21.9, p = 0.029).
Severe infections occurred in 47% of the C1q deficient patients with SLE as well 
as in 53% of the C1q deficient patients without SLE (OR: 1.1, 95% CI: 0.3-4.9, p = 
0.881).
All patients had been vaccinated against the regular childhood diseases such as 
measles, diphtheria, tetanus and poliomyelitis. One patient did receive vaccinations, 
but no live-attenuated vaccines. Patients with C1q deficiency are vulnerable 
for infectious diseases and although it would be obvious to provide additional 
vaccinations, not all individuals received such vaccinations. From the 45 C1q 
deficient individuals 30 individuals received additional vaccinations. The additional 
vaccinations of some patients were against Pneumococcus, Meningococcus, 
Hepatitis B and the seasonal influenza vaccinations [32]. 
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Treatment and outcome
The treatment of C1q deficient patients consisted so far mainly of immunosuppressive 
therapy such as corticosteroids for SLE or (prophylactic) antibiotic therapy for 
infections. Other frequently used drugs were chloroquine and hydroxychloroquine 
as maintenance therapy, while major flares have been treated with rituximab and 
cyclophosphamide.  
The lack of C1q itself has been reversed using fresh frozen plasma (FFP) in 13 out 
of 45 patients (Table 2). In most patients the FFP is given at weekly intervals, but 
C1q levels peak early and then decline fast after an infusion [26].
HSCT has been attempted in three C1q deficient patients [29-31]. The allogeneic 
HSCT has been performed to restore C1q production and mainly treat SLE, but also 
the immunodeficiency, in C1q deficient children.  In all patients the HSCT procedure 
was successful and normal C1q levels in plasma were obtained. Currently two 
patients are doing well whereas the other one died of a intracerebral hemorrhage. 
The latter child was already in a relatively poor condition prior to HSCT. Despite 
major progress in the field of HSCT, this procedure still has a significant risk profile. 
From the questionnaire it became clear that several clinicians considered HSCT for 
their patient but they considered the severity of the clinical symptoms not sufficient 
to proceed or they reported that no sufficiently matching donor was available to 
perform HSCT.
In total 9 (20%) patients died during follow-up. The cause of death of 5 C1q deficient 
patients was septic shock. Other causes of death were bacterial meningitis, 
gastrointestinal bleeding, Pneumocystis jirovecii pneumonia and cerebral 
haemorrhage. It is important to note that except for one patient all fatalities occurred 
in the age group below 20 years (Figure 1). However, the limited follow-up time of 
the patients in this cohort as a whole does not yet allow strong conclusions. 
Figure 2. Frequency of 4 milder infections in times per year.
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Figure 3. Estimated quality of life and survival analysis.
A. Estimated quality of life, as reported by the treating physicians. The median quality of life is 7.
B. Estimated life expectancy (Kaplan-Meier survival curve) of C1q deficient patients. O = Complete 
(deceased), + = Censored (at last date of follow up).
Estimates of the quality of life
In the questionnaire we asked the treating clinicians to give an estimation of the 
quality of life of the C1q deficient patient(s). Due to the variability of the clinical 
presentation of C1q deficiency the estimates of the quality of life varied widely. 
Remarkably most of the C1q deficient patients are doing well and on a scale from 
1-10 (1 very poor – 10 great) the median score was 7 (Figure 3A). 
A total of 80% of the C1q deficient patients in this study were still alive with a median 
age of 19 years and a median quality of life of 7, range (1-10). The 20% of the C1q 
deficient patients who had died had had a low quality of life (2.44, range (1-6), p = 
0.013) and suffered of recurrent infections. In order to have a reference group for 
the quality of life analyses we asked the clinicians to score also the quality of life of 
the two SLE patients they most recently examined in their clinic. Also for this group 
we obtained a median score of 7 (N=7). 
The estimated overall survival time (Kaplan-Meier) of the reported C1q deficient 
patients was evaluated (Figure 3B). In children (less than 20 years old) mortality 
was estimated to 20%. Moreover, the estimated median survival time seems to be 
at least 50 years of age although the estimation may not be reliable due to the rather 
low number of cases.
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Discussion
With this survey we have collected data on the current age, clinical manifestations 
and quality of life of patients suffering from C1q deficiency. Surprisingly we noticed 
clear differences. C1q deficiency is associated with a high case-fatality and 
with early onset of lupus-like disease or full blown SLE in the majority of cases. 
However, there are also individuals who only suffer from infections without signs of 
autoimmune disease as well as a sizable group, who are relatively or completely 
free from symptoms with an excellent quality of life. Until now no data were available 
on life expectancy and quality of life of individuals with C1q deficiency. It has 
been described that the course of C1q deficiency is variable [21]. By sending 
questionnaires to the clinicians who are currently treating C1q deficient patients or 
have treated deceased patients, we now have a first impression on life expectancy, 
cause of death, quality of life and treatment regimens. In this study there are some 
limitations in the use of the questionnaires. We received completed questionnaires 
covering 45 C1q deficient individuals. Although this is more than 70% of the 
published cases (as is common for questionnaire based studies [33]), it could 
reflect a selection bias. Even though this is an international study it may not be a 
completely worldwide study as C1q deficient individuals in many countries may 
have been missed.  The cases for which we did not receive a response were not 
restricted to a certain geographical region.
Although C1q deficiency has been reported to occur in many countries around the 
world we noticed that most patients in this study had their origin from the Middle 
East, which may reflect to a higher frequency of consanguineous unions in this area 
[3, 34].
The mutations associated with C1q deficiency include deletions; changes of amino 
acids or changes in intron-exon splice sites [5, 7, 22]. As most of the mutations 
result in a condition where no C1q protein is secreted there does not seem to be 
an obvious relationship between the mutation involved and the clinical outcome 
of C1q deficiency [4]. Especially since within one family the clinical presentation 
can vary significantly among individuals homogenous for the same mutation. 
Differences in phenotype of patients illustrate that other unidentified (epi)-genetic 
and environmental influences are also important in the overall clinical picture [35, 
36]. Understanding what factors determine that some C1q deficient individuals 
remain asymptomatic whereas others develop SLE, infections or both, will be an 
important, yet difficult, focus of future studies.
The use of fresh frozen plasma as a treatment option is well described and was 
applied in 14 patients[23, 26]. In mouse studies bone marrow transplantation in 
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C1q deficient mice showed positive results and was suggested as a therapeutic 
option in patients suffering from severe disease [27, 28]. 
From the questionnaires it became clear that in a substantial number of cases 
clinicians have considered stem cell transplantation. On the one hand the HSCT 
should be performed in a patient that is not marked by the underlying SLE or 
infections, whereas on the other hand performing a HSCT in a patient that is (still) 
doing fine may not counterbalance the potential risks involved in HSCT. This survey 
shows that there is a substantial percentage of C1q deficient individuals without 
any clinical or serological markers of disease. Whether HSCT or gene therapy could 
be a good option for individuals who have not yet suffered major health problems 
depends on better insight into the prognosis and on the improvement of these 
treatments in the future. 
Our data show that even during follow up there is enormous diversity in the clinical 
presentation and severity of symptoms in persons that are deficient for C1q. 
Even though this case series comprised 45 individuals (comprising the majority 
of cases known to date) there is no clear algorithm to describe how to manage 
C1q deficiency. From the data it seems that once the C1q deficient patients reach 
adulthood that then the chance of fatal infections is reduced. However, follow up 
data from a longer period is needed to address this question. Remarkably, patients 
with C1q deficiency showed also other complications. In the questionnaires we 
received information on two C1q deficient patients who were diagnosed with 
Moyamoya disease and another patient with signs of Rothmund-Thomson syndrome 
[24]. The relation between C1q deficiency and to these unexpected complications 
is not known, but this will likely contribute to a reduction of the life expectancy of 
these patients.
Conclusion
With this overview we aimed to bring together the currently available information on 
whether, when and which clinical manifestations occur in C1q deficient patients to 
be able to make the best possible estimation regarding current treatment options 
like immunosuppressive drugs, FFP or HSCT. From this survey it became clear that 
there is enormous diversity in the clinical presentation and severity of symptoms in 
persons that are deficient for C1q. 
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Abstract
C1q deficiency is a rare immunodeficiency, which is strongly associated with the 
development of systemic lupus erythematosus (SLE). A mutation in one of the 
C1q genes can either lead to complete deficiency or to low C1q levels with C1q 
polypeptide in the form of low-molecular weight (LMW) C1q. Patients with C1q 
deficiency mainly present with cutaneous and renal involvement. Although less 
frequent, neuropsychiatric (NP) involvement has also been reported in 20% of the 
C1q-deficient patients. This involvement appears to be absent in other deficiencies 
of early components of the complement classical pathway (C1r/C1s, C2 or C4 
deficiencies). We describe a new case with C1q deficiency with a homozygous 
G34R mutation in C1qC producing LMW-C1q presenting with a severe SLE flare 
with NP involvement. The serum of this patient contained very low levels of a 
LMW variant of C1q polypeptides. Cell lysates contained the three chains of C1q 
but no intact C1q was detected, consistent with the hypothesis of the existence 
of a LMW-C1q. Furthermore we provide a literature overview of NP-SLE in C1q 
deficiency and hypothesise about the potential role of C1q in the pathogenesis of 
NP involvement in these patients. The onset of NP-SLE in C1q deficient individuals 
is more severe when compared with complement competent NP-SLE patients. An 
important number of cases present with seizures and the most frequent findings in 
neuroimaging are changes in basal ganglia and cerebral vasculitis. 
A defective classical pathway, because of non-functional C1q, does not protect 
against NP involvement in SLE. The absence of C1q and subsequently some of its 
biological functions may be associated with more severe NP-SLE.
Introduction
C1q-deficiency is a rare autosomal recessive inherited defect of the complement 
system caused by mutations occurring in one of the three C1q genes (C1qA; C1qB; 
C1qC). [1] Up to date, three different categories of mutations according to C1q 
level have been described. Apart from nonsense mutations and missense mutations 
leading to absence of C1q in serum, a missense mutation with detectable C1q 
levels has been described. [2] In the last case, some authors have demonstrated a 
low gradient density of C1q compared with healthy controls and is therefore called 
low molecular weight C1q (LMW-C1q). [3, 4] Until now, a total of 77 C1q-deficiency 
patients in 49 families have been described. [5-7] An important variability in 
clinical presentation and outcome of these patients has been observed, ranging 
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from asymptomatic patients to life-threatening encapsulated bacterial infections. 
[7-9] C1q-deficiency is also strongly related to systemic lupus erythematosus 
(SLE), being so far the most penetrant genetic factor predisposing to this disease. 
From all patients described, a total of 85% presented SLE-like symptoms while 
around 50% have been addressed as SLE according to the American College of 
Rheumatology diagnostic criteria. [1, 3, 4, 7, 8] Cutaneous involvement, oral ulcers 
and renal involvement are the most consistent manifestations. Although nervous 
system involvement is less frequent, with only 15 patients described, it can lead to 
severe neuropsychiatric (NP) symptoms. 
Several reports, based on mouse models and/or in-vitro experiments describe that 
C1q plays a role in the brain during different developmental stages. C1q can be 
neuroprotective in the context of neurotoxicity induced by beta-amyloid, [10, 11] 
but it is also reported to be involved in damage in the context of Alzheimer’s disease 
[12]. It remains to be established to what extent C1q is involved in cognitive (dys)
function in humans and how and in which stages of development C1q is protective 
or damaging to brain tissue.
In this report we describe a new C1q deficient patient with a G34R mutation in the 
C1qC chain leading to severe NP-SLE and review 15 SLE cases with C1q deficiency 
and NP involvement in the literature. Furthermore we analyse the biochemical 
structure of LMW-C1q in serum and in cell lysates.
Patient and methods
Clinical presentation of the C1q deficient patient
A 24-year-old Dutch man was admitted to our hospital with a 2-day history of 
progressive weakness and sensory loss of the left arm, visual field loss on the left 
side and subjective cognitive complaints with regard to concentration and memory. 
He had been diagnosed with a SLE-like illness associated with C1q deficiency at 
the age of 10 months when he presented a butterfly rash and antinuclear antibodies 
(ANAs) positivity. The C1q deficiency was caused by a homozygous g.5499G>A 
mutation at the C1qC gene, resulting in a G34R change in the C1q protein. 
Consanguinity was not reported. 
At the age of three he developed polyarthritis, which was successfully treated with 
naproxen. At the age of seven he was admitted due to a relapsing polyarthritis 
and subacute cutaneous lupus, fever, aphthous ulcers, sunlight hypersensitivity, 
malaise and positive antibodies including ANAs, anti-Ro, anti-RNP70 and Sm. SLE 
was diagnosed and hydroxychloroquine 200 mg was started. Examination of the 
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past medical history also included frequent upper airway and ear infections during 
the first 3 years of his life, Pertussis infection at the age of four, relapsing impetigo 
with a Staphylococcus aureus septicemia at the age of 19 years and relapsing virus 
varicella zoster infection after the age of 20.
On the current admission, the patient’s body temperature was 37.7°C and blood 
pressure was 100/60 mmHg. Physical examination was remarkable with a butterfly 
rash (figure 1A), severe sensory loss of the left arm, hyperesthesia of the left hand 
and homonymous hemianopsia of the left side. Laboratory tests revealed increased 
ESR (63 mm/h; normal <15) and CRP (13.7 mg/L; normal <5), a normal haemoglobin 
and complete blood count. Except for a reduced serum albumin level (31 g/L; 
normal 34-48), electrolytes, serum cholesterol, renal and liver testing were normal. 
Analysis of the urine was normal without casts or dysmorphic red cells. Protein 
excretion was 9.87 g/24h. The antibody profile was positive for ANAs, anti-Ro (>240 
U/mL, normal <7), anti-RNP70 (79 U/mL, normal <5) and anti-Sm antibodies (>120 
U/mL, normal <5). Anti-double-stranded DNA, anticardiolipin antibodies, Beta-2-
GP1 antibodies, lupus anticoagulant, anti-phospholipase-A2-Receptor (PLA2R) 
and Anti-C1q autoantibodies were negative. At this time analysis of complement 
showed a classical pathway activity of 0% (normal > 74%), a low alternative 
pathway activity (22%, normal >39%), a low level of C1q (21 mg/L, normal 102–
171 mg/L), whereas C3 (1.4 g/L, normal 0.9–2.0 g/L) and C4 (396 mg/L, normal 
95–415 mg/L) were in the normal range. Blood and urine cultures were negative. 
Findings from the renal biopsy were compatible with a class V lupus nephritis, 
with a ‘nearly full house’ immunostaining showing a strong granular staining for 
IgG and a moderate granular staining for C3, both along the glomerular basement 
membrane; a slight granular staining for IgA and IgM, and kappa and lambda 
light chains, sometimes also in mesangial areas, but no staining for C1q (Figure 
1C). Electron microscopy revealed subendothelial, subepithelial and mesangial 
deposits (Figure 1D and E). A low Minimental State Examination for the age and 
education of the patient (24, range 0-30) was found. A brain computed-tomography 
(CT) scan demonstrated a hyperdensity at the right frontal and parietal lobes and 
a contrast enhanced CT showed a bilateral filling defect in the transverse sigmoid 
sinus. A Magnetic Resonance Imaging (MRI) showed multifocal diffuse grey matter 
hyperintensities located in the fronto-temporal right lobe and high-intensity area 
on T2 in multiple regions of the right frontal and parietal lobes with high-intensities 
on the diffusion weighted imaging study (Figure 1B). A CT-angiography showed 
no signs of cerebral vasculitis. A diagnosis of lupus nephritis type V and NP-SLE 
with both inflammatory and ischemic phenotype were established. The patient was 
treated with daily clopidrogrel 75 mg and intravenous methylprednisolone 1 gr 3 
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days plus oral prednisone 1 mg/kg/d in a tapering dose, and monthly intravenous 
cyclophosphamide 1 gm/m2 for six months. Proteinuria improved dramatically in 
the first week and homonymous hemianopsia and cognitive dysfunction resolved 
after 2 weeks. After 3 months the patient still presented a mild sensory loss of the 
left arm. Both the patient and his parents provided informed consent for the studies.
Figure 1. Clinical presentation of the 
C1q deficient patient. A. Malar rash and 
discoid lupus leading to mild scarring 
and atrophy B. 3-Tesla MRI brain (FLAIR 
image): multifocal diffuse grey matter 
hyperintensities located in the fronto-
temporal right lobe and high-intensity area 
in multiple regions of the right frontal and 
parietal lobes C. Immunofluorescence 
staining of IgG deposition, C3 deposition 
and C1q deposition on the kidney. D. 
Electron micrograph of the sub-endothelial 
deposition (arrows) of electron dense 
material. E. Electron micrograph of 
mesangial deposition (stars) of electron 
dense material..











Serum and PBMCs, isolated by Ficoll-Paque density gradient centrifugation were 
collected from the patient and an age matched control. During the admission a 
kidney biopsy was performed.
Microscopy
Slides for light microscopy evaluation were stained by hematoxylin and eosin, 
PAS and silver staining. Immunofluorescent stainings on cryostat sections were 
performed for IgA, IgG, IgM, C3, c1q and kappa and lambda light chains. Part of 
the renal specimen was used for electron microscopy. Pictures were taken with a 
JEM-1011 electron microscope (JEOL USA, Inc.) at various magnifications. 
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Gel filtration
Gel filtration experiments were carried out using the Äktaprime plus system (GE 
Healthcare, 11001313). 500 ul of filtered serum sample, either the healthy control 
serum or serum from the C1q deficient patient, was run through a Hiload Superdex 
Prep grade 200 16/600 column (GE Healthcare), using PBS as the running buffer. 
Fractions of 1ml were collected starting after half an hour for the duration of 
approximately 50 fractions. The protein levels in the fractions were analysed using 
a Piercetm BCA Protein Assay Kit (ThermoFisher Scientific).
C1q ELISA
The levels of C1q in serum and supernatants were measured using an in-house 
developed ELISA. Maxisorp plates (Nunc) were coated with mouse anti-human 
C1q (Department of Nephrology, LUMC) in coating buffer (0.1 M NA2CO3, 0.1 
M NaHCO3, pH 9.6) overnight at 4°C. Plates were washed in PBS/0.05% Tween 
(PBS-T, Sigma). Then the wells were blocked with PBS/1% BSA for 1 hour at room 
temperature. After washing, the patient serum and control serum were added to the 
wells in a two-fold dilution series starting from 1:100 diluted in PBS/1% BSA/0.05% 
Tween (Sigma). After incubation for 1 hour at 37°C, the plates were incubated with 
rabbit anti-human C1q (DAKO) for 1 hour at 37°C and as detection antibody goat 
anti-rabbit HRP (DAKO) was used. Finally the substrate was added using ABTS 
(sigma). The C1q levels were measured at an absorbance level of 415 nm.
Western blot
Using western blot the composition of C1q was examined by detection of the three 
chains of the C1q protein. Due to the low amount of C1q present in the serum 
of the patient, we applied ten times more serum of the patient than the healthy 
donor. Cell lysates and supernatants of stimulated and unstimulated PBMCs of the 
healthy control and the patient were used in the same amount in reduced and 
non-reduced SDS conditions. The western blot was performed using previously 
described methods. [9]
Reconstitution complement activity assay
To exclude the possibility that next to C1q deficient the patients sample would 
also be deficient for C1r or C1s we performed assays to measure activation of 
the classical pathway of the patient serum by reconstitution of purified C1q. Plates 
coated with human IgG were incubated with 1% serum of the patient (diluted in 
GVB++; 0.1 % gelatin, 5 mM Veronal, 145 mM NaCl, 0.025 % NaN3, 0.15 mM CaCl, 
0.5 mM MgCl, pH 7.3) with or without addition of purified C1q (Quidel) in different 
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concentrations. As a read-out C4 deposition was measured.
Sequencing
Genomic DNA was extracted from blood collected with tubes supplemented with 
EDTA. Sequencing of the complete C1q genes (C1qA, C1qB and C1qC), of both 
introns and exons was performed as before. [9] Deep-sequencing was performed 
using the 454 NGS Roche GS FLX Titanium platform. Data were compared to 
internal controls and to Human Genome build 19 as well as Human_v37_2 de 
dbSNP database v132 using the NextGENe software package for Next Generation 
Sequence Analysis (NGS) from Softgenetics. The effect of the mutation on splicing 
was in-silico analysed using the NetGene2 Server, http://www.cbs.dtu.dk/services/
NetGene2/. 
Results
Detection of LMW-C1q in serum
With deep sequencing we identified a homozygous g.5499G>A mutation in the 
C1qC gene, resulting in a change in the C1qC chain where glycine was changed 
into an arginine at position 34 (G34A), while both parents show a heterozygous state 
of the mutation (Figure 2A). The routine diagnostics laboratory reported the patient 
to be completely lacking classical pathway activity (Figure 2B). This is compatible 
with a C1q deficiency, but to exclude that next to C1q also other factors would be 
deficient in the patient we performed a reconstitution assay where we add purified 
C1q to the serum of the patient and analyse C4 deposition. To compare the activity 
we performed the same analysis with C1q depleted serum. After adding purified 
C1q we were able to detect C4 deposition at a similar range as C1q depleted 
serum reconstituted with pC1q (Figure 2C). This indicated that the patient was able 
to produce C1r and C1s, C2 and C4 and together with purified C1q was able to 
activate the classical pathway. Furthermore, we were also able to measure C5b9 
and C3c deposition. This implied that there were no other complement deficiencies 
downstream in the complement system (Figure 2D&E).
Using ELISA we could detect a decreased amount of C1q in the patient compared 
to the control samples (Figure 3A). We used western blot to examine the molecular 
structure of C1q in the patient serum. In reducing conditions all the three chains of 
the correct size are detected. However, using non-reducing conditions the dimers 
of C1q (2 x A-B and 1 x C-C) show an abnormal pattern. Using non-reducing/
non-denaturing conditions we were able to detect high molecular weight C1q in 
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Figure 2. Genetic analysis of the patient and complement activation assays. A. Data obtained from 
deep sequencing show a G34R mutation in the C1qC chain. B. Measurement of the alternative pathway 
(AP) (Wieslab), classical pathway (CP) (Wieslab), C1q, C3 and C4 with nephelometer measurement in 
the diagnostic laboratory. C. Reconstitution of the classical pathway by adding different concentrations 
of purified C1q to the patient serum. As a positive control normal human serum was used (NHS) and 
as a negative control heat inactivated NHS (ΔNHS) was used. C4 deposition was used as detection 
antibody. D. C5b9 deposition after adding purified C1q to the patient serum and C1q depleted serum. 
E. C3c deposition.
the healthy control but not in the patient, suggesting that the C1q of the patient is 
of a LMW species (Figure 3B). With the usage of gel filtration the serum samples 
of the healthy donor and the patient were fractionated on size and with a BCA the 
amount of protein was analysed. While the protein profiles of both gel filtrations are 
similar, the location of C1q in the elution profiles is clearly different (Figure 3C&D). 
Please note that since the serum of the patient was very low in C1q concentration 
we had to use different dilutions for the patient and the control in the ELISA to detect 
the presence of C1q in the fractions. These size-exclusion chromatography data 
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Figure 3. Detection of LMW-C1q in serum. A. C1q ELISA by using a dilution range of the serum of 
the C1q deficient patient (▲), age-matched control (■) and NHS (●) as extra control. B. Western blot 
analysis of the serum in reduced, non-reduced and non-reduced/non-denatured conditions. As positive 
control an age-matched control is used. Patient serum was diluted 50x and the healthy control 500x. C. 
Protein analysis using a BCA protocol and C1q ELISA of different fractions after gel filtration of the serum 




















































































































































Composition of C1q in PBMC of the C1q deficient patient
To further examine the production of C1q by the cells of the patient by Western 
Blot, we stimulated PBMCs of the patient and the control with DXM and IFN-γ to 
upregulate the C1q production. Compared to the serum we loaded the same 
amount of lysate and supernatant to the lanes. In reducing conditions we see all 
the three C1q chains in the lysate of the PBMCs (Figure 4A). The dimers of C1q 
can also be detected in the lysates of the PBMCs from the patient. However, in 
non-reducing non-denaturing conditions, the dimers of C1q are detected, while 
additional bands are seen in the PBMCs of the patients, which may indicate the 
presence of intracellular LMW-C1q (Figure 4B).
To examine the composition of secreted C1q, the supernatant of the PBMCs 
was analysed using western blot. The three chains of C1q were detected in the 
control supernatant as well as in the patient supernatant in reducing conditions. 
Surprisingly, the amount of C1q seems comparable between the patient and the 
control (Figure 4C). In non-reducing, non-denaturing conditions the high molecular 
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Figure 4. Analysis of stimulated cells from the C1q-deficient patient on the presence of C1q, A. 
Western blot analysis of cell lysates from stimulated PBMCs in reducing conditions, B. non-reducing 
and non-denaturing conditions. C. Western blot analysis of the supernatant of the PBMCs from the 
patient and the healthy donor (control) after 72h of culturing in reducing conditions. D. In non-reducing 
and non-denatured conditions. The cell lysates and supernatant were added in the same amount. E. A 
schematic representation of intact C1q and LMW-C1q. In LMW-C1q positive charges are introduced in 
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size of C1q (460 kDa) is detected only in a very low concentration compared to the 
supernatant of the healthy control (Figure 4D).
 
C1q deficiency and NP-SLE
We performed an extensive electronic literature search from 1980 to 2016 using 
online databases (PubMed, Embase, Medline). We found 15 C1q-deficient patients 
with NP-SLE. All these patients presented at least one major central nervous system 
(CNS) manifestation.  Clinical and neuroimaging characteristics of these patients 
are summarized in Supplementary Table 1. Among all C1q-deficient patients 
C1q deficiency and NPSLE | 77
4
with NP-SLE described so far in the literature, seizures was the most frequent 
NP symptom presented (10 patients; 67%). [6, 13-20] Furthermore, five patients 
(33%) presented with a series of severe non-specific NP symptoms characterized 
by encephalopathy and difficulties to walk associated with cerebral infarcts and 
thought to be related with a cerebral vasculitis. [5, 13, 19-21] Transverse myelitis [6, 
22] and psychosis [14, 22] were also present in 2 patients (13%). Neuroimaging of 
the brain showed as more frequent finding affection of basal ganglia (calcification 
or ischemic lesions) in 40 % of the cases [16, 17, 19-21, 23] followed by cerebral 
vasculitis (27%) [13, 15, 20, 21] and brain atrophy (20%) [6, 17, 24].
Discussion
The present study investigated an extremely rare case of C1q-deficiency due to non-
functional LWM-C1q associated with a severe clinical phenotype presenting with 
membranous lupus nephritis and a mixed inflammatory and ischemic NP-SLE. C1q 
deficiency is a very strong susceptibility factor for the development of SLE where 
patients mainly present during childhood with skin or renal involvement and less 
frequently also with neuropsychiatric involvement. [7] Interestingly, although all the 
deficiencies of early components of the complement classical pathway are known to 
be a susceptibility factor for the development of SLE-like disease, neuropsychiatric 
involvement appears to be absent in C1r/C1s, C2 or C4 deficiencies. [24, 25] This 
makes us to speculate about the possible role of C1q in the underlying process 
leading to NP-SLE. 
NP involvement in SLE-related C1q-deficiency presents with severe major CNS 
manifestations and its prevalence seems to be slightly higher than in complement 
competent NP-SLE patients (20% vs. <5%). [26] Seizures were the most common 
manifestation, presented in 60% of NP-SLE patients. In animal models, the production 
of C1q by neuronal cells was reported to lead to opsonisation of synapses in the 
developing postnatal CNS, that are next eliminated by microglia. [27] Several 
studies in murine models have described that C1q plays a role in the brain during 
different developmental stages. A neuroprotective role for C1q was reported in the 
context of beta-amyloid-induced neurotoxicity [10, 11] , while on the other hand, 
C1q is reported to be involved in damage in the context of Alzheimer’s disease. [12] 
The complement system can hence facilitate normal neuronal development and 
protect against damage or contribute to neurodegenerative disease depending on 
yet to be identified triggers and timing. Currently it has not been formally studied 
whether C1q deficient patients have cognitive impairments. The neurological status 
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of the current case completely normalised after the successful treatment of the SLE 
flare with immunosuppression, without any residual cognitive impairment. Moreover, 
studies using C1q knockout mice have demonstrated how a defective neocortical 
pruning of excessive excitatory synapses in these animals results in spontaneous 
and evoked epileptiform activity and increased intracortical excitatory connectivity. 
[28, 29] This may explain the increased prevalence of seizures among these 
patients. Of note, neuroimaging demonstrated that a total of 40% of patients with 
C1q-deficiency presenting with NP-SLE showed involvement of the basal ganglia 
and in 27% of these patients findings were compatible with cerebral vasculitis. 
Neuroimaging changes in basal ganglia have been rarely reported in SLE patients. 
It has been suggested that these findings may represent vasogenic oedema and 
vascular changes occurring due to a vasculitic process localized in the basal 
ganglia probably due to immune-mediated underlying pathogenesis or effect of 
inflammation. Moreover, these MRI findings have been described to be reversible 
after starting immunosuppressive therapy. [30] SLE associated vasculitis may be 
associated with the deposition of immune complexes (ICs) in the endothelium. The 
deposition of these ICs may lead to endothelial cell activation and inflammatory 
cell infiltration. [31] Previous reports have proposed an important role of C1q in 
the clearance of apoptotic cells and circulating ICs. [32, 33] Non-cleared debris 
due to absence of C1q may lead to helper T cells stimulation and autoantibody 
production. [34, 35] Furthermore, in the last years C1q has been demonstrated 
to be of importance in vascular endothelial permeability and integrity. C1q and 
mannose binding lectin have been reported in in-vitro studies to help in the removal 
of atherogenic lipoproteins, which has been proposed as a link between C1q 
deficiency and cardiovascular disease in SLE, as seen in our patient. [36, 37] 
Globally more than 60 patients are described with a C1q deficiency mostly due to a 
homozygous mutation. From these patients, 6 have the g.5499G>A mutation resulting 
in a G34A amino acid change and C1q deficiency. [4, 14, 16, 17, 20, 38] Previous 
case reports that described the G34R mutation suggested the development of 
LMW-C1q, which is known as a non-functional C1q. In this study we demonstrate a 
C1q deficient patient with a low level of circulating C1q and an absence of classical 
pathway activity recorded over a long time period. Using sequencing we confirmed 
a homozygous G34R mutation. As suggested in previous studies, we also observed 
that the C1q present in this patient is LMW-C1q. Using western blot and gel filtration 
of the patient serum we detected a different molecular size of C1q in the patient 
serum at low concentrations. When we analysed the production of C1q by PBMCs 
we could detect all three C1q chains at a same concentration intracellularly, but after 
analysing C1q in the supernatant in non-reducing and non-denaturing conditions 
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almost no fully folded C1q was detected. This confirms that the patient is able to 
produce all C1q chains but is unable to fold a complete functional C1q molecule. 
It is conceivable that the incorrectly folded C1q polypeptide chains have a strongly 
reduced half-life. Circulating C1q was completely absent after a flare of NPSLE. 
This may suggest that there is consumption of the little C1q polypeptide that the 
patient produces. However, in the renal biopsy no C1q was detected, which could 
also indicate that it is not consumption of LMW C1q but rather a reduced production 
at the time of flare. Although temporary expression of LMW-C1q has been reported 
to occur during SLE flares or even in healthy persons, this production is temporary 
and involves only part of the total C1q pool. [39, 40] In the current patient the 
production of LMW-C1q is genetically regulated and permanent and results in a 
completely defective classical pathway. 
In conclusion, NP-SLE is a rare but severe complication in C1q-deficiency patients 
that must be diagnosed and treated promptly. The low level of LMW C1q observed 
in the patient did not allow any classical pathway activity, making the patient 
functionally C1q deficient. The role of C1q or its absence in the pathogenesis of 
NP-SLE merits further studies
Acknowledgments
We express our gratitude towards the patient and his parents for their kind 
willingness to participate and for their support. In addition we acknowledge the 
financial support from the IMI JU funded project BeTheCure, contract no 115142-2, 
L.A.T. is supported by a ZON-MW Vidi grant. 
80 | C1q deficiency and NPSLE
4
References
1. Schejbel, L., et al., Molecular basis of hereditary C1q deficiency--revisited: identification of several 
novel disease-causing mutations. Genes Immun, 2011. 12(8): p. 626-34.
2. Petry, F., et al., Non-sense and missense mutations in the structural genes of complement 
component C1q A and C chains are linked with two different types of complete selective C1q 
deficiencies. J Immunol, 1995. 155(10): p. 4734-8.
3. Jlajla, H., et al., New C1q mutation in a Tunisian family. Immunobiology, 2014. 219(3): p. 241-6.
4. Walport, M.J., K.A. Davies, and M. Botto, C1q and systemic lupus erythematosus. Immunobiology, 
1998. 199(2): p. 265-85.
5. Olsson, R.F., et al., Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Human 
C1q Deficiency: The Karolinska Experience. Transplantation, 2016. 100(6): p. 1356-62.
6. Roumenina, L.T., et al., Functional complement C1q abnormality leads to impaired immune 
complexes and apoptotic cell clearance. J Immunol, 2011. 187(8): p. 4369-73.
7. Stegert, M., M. Bock, and M. Trendelenburg, Clinical presentation of human C1q deficiency: How 
much of a lupus? Mol Immunol, 2015. 67(1): p. 3-11.
8. van Schaarenburg, R.A., et al., Marked variability in clinical presentation and outcome of patients 
with C1q immunodeficiency. J Autoimmun, 2015. 62: p. 39-44.
9. van Schaarenburg, R.A., et al., Identification of a novel non-coding mutation in C1qB in a Dutch 
child with C1q deficiency associated with recurrent infections. Immunobiology, 2015. 220(3): p. 
422-7.
10. Benoit, M.E. and A.J. Tenner, Complement protein C1q-mediated neuroprotection is correlated 
with regulation of neuronal gene and microRNA expression. J Neurosci, 2011. 31(9): p. 3459-69.
11. Pisalyaput, K. and A.J. Tenner, Complement component C1q inhibits beta-amyloid- and serum 
amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem, 
2008. 104(3): p. 696-707.
12. Hong, S., et al., Complement and microglia mediate early synapse loss in Alzheimer mouse models. 
Science, 2016. 352(6286): p. 712-6.
13. Hannema, A.J., et al., SLE like syndrome and functional deficiency of C1q in members of a large 
family. Clin Exp Immunol, 1984. 55(1): p. 106-14.
14. Kirschfink, M., et al., Complete functional C1q deficiency associated with systemic lupus 
erythematosus (SLE). Clin Exp Immunol, 1993. 94(2): p. 267-72.
15. Mehta, P., et al., SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. 
Rheumatology (Oxford), 2010. 49(4): p. 823-4.
16. Orihara, T., et al., Selective C1q deficiency in a patient with systemic lupus erythematosus. Br J 
Dermatol, 1987. 117(2): p. 247-54.
17. Slingsby, J.H., et al., Homozygous hereditary C1q deficiency and systemic lupus erythematosus. 
A new family and the molecular basis of C1q deficiency in three families. Arthritis Rheum, 1996. 
39(4): p. 663-70.
18. Steinsson, K., et al., Selective complete Clq deficiency associated with systemic lupus 
erythematosus. J Rheumatol, 1983. 10(4): p. 590-4.
19. Troedson, C., et al., Systemic lupus erythematosus due to C1q deficiency with progressive 
encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy. Lupus, 
2013. 22(6): p. 639-43.
20. Tsuge, I., et al., Hyper IgM syndrome and complement Clq deficiency in an individual with systemic 
lupus erythematosus-like disease. Clin Exp Rheumatol, 2010. 28(4): p. 558-60.
21. Vassallo, G., et al., Clinical variability and characteristic autoantibody profile in primary C1q 
C1q deficiency and NPSLE | 81
4
complement deficiency. Rheumatology (Oxford), 2007. 46(10): p. 1612-4.
22. Jesus, A.A., et al., Complement and antibody primary immunodeficiency in juvenile systemic lupus 
erythematosus patients. Lupus, 2011. 20(12): p. 1275-84.
23. Marquart, H.V., et al., C1q deficiency in an Inuit family: identification of a new class of C1q disease-
causing mutations. Clin Immunol, 2007. 124(1): p. 33-40.
24. Pickering, M.C., et al., Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv 
Immunol, 2000. 76: p. 227-324.
25. Macedo, A.C. and L. Isaac, Systemic Lupus Erythematosus and Deficiencies of Early Components 
of the Complement Classical Pathway. Front Immunol, 2016. 7: p. 55.
26. Kampylafka, E.I., et al., Incidence and prevalence of major central nervous system involvement in 
systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS One, 2013. 8(2): 
p. e55843.
27. Stevens, B., et al., The classical complement cascade mediates CNS synapse elimination. Cell, 
2007. 131(6): p. 1164-78.
28. Chu, Y., et al., Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc Natl Acad 
Sci U S A, 2010. 107(17): p. 7975-80.
29. Ma, Y., et al., Remodeling of dendrites and spines in the C1q knockout model of genetic epilepsy. 
Epilepsia, 2013. 54(7): p. 1232-9.
30. Sato, S., et al., Reversible basal ganglia lesions in neuropsychiatric lupus: a report of three pediatric 
cases. Int J Rheum Dis, 2014. 17(3): p. 274-9.
31. Sun, W., et al., Immune complexes activate human endothelium involving the cell-signaling HMGB1-
RAGE axis in the pathogenesis of lupus vasculitis. Lab Invest, 2013. 93(6): p. 626-38.
32. Nauta, A.J., et al., Direct binding of C1q to apoptotic cells and cell blebs induces complement 
activation. Eur J Immunol, 2002. 32(6): p. 1726-36.
33. Santer, D.M., et al., C1q deficiency leads to the defective suppression of IFN-alpha in response to 
nucleoprotein containing immune complexes. J Immunol, 2010. 185(8): p. 4738-49.
34. Clarke, E.V., et al., Complement protein C1q bound to apoptotic cells suppresses human 
macrophage and dendritic cell-mediated Th17 and Th1 T cell subset proliferation. J Leukoc Biol, 
2015. 97(1): p. 147-60.
35. Martin, M. and A.M. Blom, Complement in removal of the dead - balancing inflammation. Immunol 
Rev, 2016. 274(1): p. 218-232.
36. Fraser, D.A. and A.J. Tenner, Innate immune proteins C1q and mannan-binding lectin enhance 
clearance of atherogenic lipoproteins by human monocytes and macrophages. J Immunol, 2010. 
185(7): p. 3932-9.
37. Prechl, J. and L. Czirjak, The endothelial deprotection hypothesis for lupus pathogenesis: the dual 
role of C1q as a mediator of clearance and regulator of endothelial permeability. F1000Res, 2015. 
4: p. 24.
38. Pickering, M.C., et al., Complement C1q and C8beta deficiency in an individual with recurrent 
bacterial meningitis and adult-onset systemic lupus erythematosus-like illness. Rheumatology 
(Oxford), 2008. 47(10): p. 1588-9.
39. Hoekzema, R., et al., Biosynthesis of normal and low-molecular-mass complement component C1q 
by cultured human monocytes and macrophages. Biochem J, 1989. 257(2): p. 477-86.
40. Hoekzema, R., et al., Significance of low molecular weight C1q in systemic lupus erythematosus. 
Ann Rheum Dis, 1990. 49(9): p. 698-704.


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Rosanne A Schaarenburg*, César Magro-Checa*, Hannelore J.L. Beaart, 
Tom W.J. Huizinga, Gerda M. Steup-Beekman, Leendert A. Trouw
*Both authors contributed equally to this manuscript
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
Lupus. 2016 Jul;25(8):878-88
Complement levels and 
anti-C1q autoantibodies in 
patients with neuropsychiatric 
systemic lupus erythematosus
86 | Complement levels and anti-C1q in NPSLE
5
Abstract
To analyse serum levels of anti-C1q, C1q circulating immune complexes 
(CIC), complement activation and complement components in systemic lupus 
erythematosus (SLE) patients during the first central nervous system neuropsychiatric 
event and to define the possible association between these results and clinical and 
laboratory characteristics.
A total of 280 patients suspected of having NP involvement due to SLE were 
recruited in the Leiden NPSLE-clinic. All SLE patients were classified according 
to the ACR 1982 revised criteria for the classification of SLE. The clinical disease 
activity was measured by the SLE Disease Activity Index 2000 (SLEDAI-2K) and NP 
diagnoses were classified according to the 1999 ACR case definitions for NPSLE. 
We measured in serum of all patients anti-C1q and C1q CIC levels, the activation 
capacity of complement (CH50 and AP50) and different complement components 
(C1q, C3, C4). 
In 92 patients the symptoms were attributed to SLE. NPSLE patients consisted of 63 
patients with focal NPSLE and 34 patients with diffuse NPSLE. Anti-C1q antibodies 
were significantly higher and CH50, AP50 and C3 were significantly lower in NPSLE 
patients compared with SLE patients without NPSLE. This association was specially 
marked for diffuse NPSLE while no differences were found for focal NPSLE. After 
using potential predictors, decreased C4 remained significantly associated with 
focal NPSLE, but only when antiphospholipid antibodies (aPL) were included in the 
model. C3 and AP50 were independently associated with diffuse NPSLE. When 
SLEDAI-2K was included in the model these two associations were lost. When 
individual NPSLE syndromes were analyzed, psychosis and cognitive dysfunction 
showed significantly lower values of complement activation capacity and all 
complement components. No significant associations were seen for other individual 
NPSLE syndromes.
The associations between diffuse NPSLE and anti-C1q, C3/AP50 and focal NPSLE 
and C4 may be explained by disease activity and the presence of aPL respectively. 
The role of complement activation and complement components in lupus psychosis 
and cognitive dysfunction merits further research.
Introduction
The complement system plays an important role in systemic lupus erythematosus 
(SLE). [1] Decreased levels of complement components, complement activation 
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and higher levels of antibodies against C1q (anti-C1q) are characteristic findings 
in active SLE. A correlation between renal involvement and circulating immune 
complexes (CIC), complement deposits and levels of anti-C1q has been found in 
SLE. [1-3] However, the pathogenic role of all these complement components in 
other organs, including the nervous system, is less clear. 
Complement factors are known to contribute to the pathology of inflammatory 
central nervous system (CNS) and neurodegenerative diseases and they have been 
proposed as one of the multiple participants in the pathogenesis of neuropsychiatric 
systemic lupus erythematosus (NPSLE). [4-6] Data from human studies are scarce 
and contradictory. Although the exact underlying mechanism remains unknown, 
complement may collaborate in blood-brain barrier (BBB) alteration, brain cell 
dysfunction or vasculopathy and accelerated atherosclerosis. [5, 7, 8] Some authors 
have found an association between NPSLE and low serum levels of C3 and C4 
complement components, while increased levels of these proteins and the soluble 
form of C5b-9 have been found in the cerebrospinal fluid (CSF) of SLE patients. 
[9-11] An enhance deposition of complement activation products on platelets has 
also been associated with the development of thrombosis in SLE, a process where 
antiphospholipid antibodies (aPL) have been reported to be collaborate notably. 
[12, 13] 
In murine models, both deletion of factor B, a key alternative pathway protein, 
and inhibition of the classical and alternative complement cascade with the 
complement inhibitor Crry, demonstrated to alleviate experimental CNS lupus. [14, 
15] In addition, selective inhibition of two complement receptors, C3aR and C5aR, 
reduced neuronal degeneration (apoptosis and gliosis) and alleviated CNS lupus 
respectively. [16, 17] C5 has also been reported to play a role in the maintenance 
of the BBB in a lupus rodent model. [18] Moreover, mice deficient in C3 and C5 
components have also been reported to be resistant to enhanced thrombosis and 
endothelial cell activation induced by aPL antibodies, ameliorating the effect and 
pointing out the important role of alternative pathway complement activation on 
aPL-antibody mediated thrombogenesis. [19, 20] 
Serum complement levels are an accessible and worldwide used biomarker of great 
value for monitoring SLE activity.  Although several studies have pointed out the 
role of the complement system in different aspects of NPSLE pathogenesis, serum 
complement components (C1q, C3 and C4), the ability to activate the complement 
system (CH50, AP50), anti-C1q and C1q CIC have never been assessed in a 
large and well defined NPSLE cohort. The aim of the current study was to analyze 
serum complement levels and anti-C1q levels during the first neuropsychiatric (NP) 
event of patients included in the Leiden NPSLE-cohort, and to define the possible 
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association between these results and clinical (NPSLE syndromes, disease activity 
and damage) and laboratory characteristics. 
Patients and methods
Patient selection and clinical evaluation
From September 2007 until September 2014, 280 consecutive patients suspected 
of having NP involvement due to SLE were referred to the Leiden NPSLE-clinic 
(Leiden University Medical Center, The Netherlands) for evaluation. All the subjects 
were admitted for 1-day and underwent multidisciplinary examination including 
neuropsychological testing, as well as extensive laboratory and radiological 
examination. A multidisciplinary consensus meeting took place soon after the 
evaluation of every patient. For further description of the multidisciplinary evaluation, 
please see reference [21]. All the patients were classified according to the 
American College of Rheumatology (ACR) 1982 revised criteria for the classification 
of SLE. [22, 23] The clinical disease activity was measured by the Systemic Lupus 
Erythematosus Disease Activity Index 2000 (SLEDAI-2K) patient. [24] For the 
better assessment of the effect of disease activity we decided to exclude the NP 
manifestations from the SLEDAI-2K. In the NPSLE group we included all patients 
having at least one NPSLE manifestation involving the CNS. NP diagnoses were 
classified according to the 1999 ACR case definitions for NPSLE syndromes and 
classified into focal and diffuse NPSLE according to these definitions. [21, 25] All 
patients with antiphospholipid syndrome (APS) had a history of anticardiolipin IgG 
or IgM (aCL), anti-beta2 glycoprotein 1 IgG or IgM (anti-β2GP1) and/or positive 
lupus anticoagulant (LAC) tests documented on two or more occasions at least 
3 months apart. Furthermore, all these patients met the Sapporo clinical criteria. 
[26] In addition, 200 healthy controls (HC), aged between 20 and 70 years, were 
included in this study. All participants in the study provided informed consent and 
the study was approved by the local medical ethics committee.
Laboratory assessment
Serum samples of all patients were collected from each subject at 08:00 AM after 
overnight fasting. The functional capability of the complement components to 
activate the complement system of the classical pathway (CH50) and the alternative 
pathway (AP50) and levels of complement components (C1q, C3 and C4) were 
measured the same day of the blood extraction in the routine clinical laboratory at 
the Leiden University Medical Center (LUMC), The Netherlands. CH50 and AP50 
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were measured using functional assays. Levels of C1q, C3 and C4 in serum were 
measured using laser nephelometry. Based on the normal limits for our laboratory, 
CH50 level < 74%, AP50 < 39%, C1q < 102 mg/l, C3 < 0.9 g/l and C4 < 95 mg/l were 
defined as low. Plasma was also prepared by centrifugation and aliquoted (500 µl) 
into polypropylene tubes before freezing and stored at - 80°C. Patient´s sera were 
kept frozen until it was analyzed for the levels of anti-C1q and C1q CIC by enzyme-
linked immunosorbent assay (ELISA). These laboratory determinations were 
performed at the Rheumatology Laboratory (LUMC, The Netherlands). Anti-C1q 
antibodies and C1q CIC in serum were measured by the QUANTA Lite ™ Anti-C1q 
ELISA and with the usage of the QUANTA Lite® C1q CIC ELISA (Inova Diagnostics, 
San Diego, CA, USA), following the protocol from the manufacturer. The reference 
intervals were defined as < 20 units/ml for anti-C1q and as < 4.4 µg Eq/ml for C1q 
CIC. These classifications were also used to classify the healthy subjects. Another 
set of blood samples was tested for aPL, anti-dsDNA, anti-Sm, anti-RNP, anti-SSA/
Ro52 and anti-SSB/La antibodies in the routine clinical laboratory at the LUMC. IgG 
anti-dsDNA antibodies were detected using the Crithidia Luciliae indirect immune 
fluorescence technique (Immunoconcepts, Sacramento, USA). IgG antibodies 
against SS-A/Ro-52, SS-B/La, Sm, RNP and IgG and IgM anti-cardiolipine and anti-
ß2-glycoproteine I antibodies were detected were determined using a Phadia® 
250 EliA fluorescence enzyme immunoassay (FEIA) (Thermo Scientific, Freiburg, 
Germany). Lupus anticoagulans (LAC) was determined using STA-Rack en STA 
Evolution coagulation analysers (Stago, Parsippany, USA).
Statistical analysis
Patients with NPSLE and SLE patients were compared with respect to demographic 
characteristics, clinical manifestations, autoantibody profile and complement 
components using χ2 test or with Fisher’s exact test and Mann-Whitney U-test when 
appropriate. Differences in anti-C1q and C1q CIC between HC, SLE and NPSLE or 
among NPSLE subgroups were analyzed by the Kruskal-Wallis test with the Dunn 
multiple comparison test or the Mann-Whitney U-test when needed. Differences in 
CH50 and AP50 between groups were compared by using one-way ANOVA test. 
χ2 test and Fisher exact test were used to compare between NPSLE subgroups 
(focal and diffuse NPSLE) and individual NPSLE syndromes and the complement 
components (C1q, C3 and C4). Odds ratios (OR) and 95% confidence intervals (CI) 
were also calculated. Five patients were included in both focal and diffuse NPSLE 
groups. We preferred this situation over leaving these patients out of the study 
completely or leave them in only one of the two groups. Binary logistic regression 
was used to ascertain the effects of age, disease activity measured by SLEDAI-
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2K and different laboratory markers including antibodies and complement on the 
likelihood to have NPSLE, focal NPSLE or diffuse NPSLE. Laboratory variables 
judged to have clinical relevance based on a priori knowledge and previous 
univariate analysis were retained in the final models. Variables of interest were 
evaluated in two models, one with complement components (C1q, C3, C4) and other 
with complement activation (CH50 and AP50), independently added to individual 
antibodies of interest (LAC, aCL, anti-dsDNA, anti-Sm and anti-C1q antibodies) and 
SLEDAI-2K. p ≤ 0.05 was considered statistically significant. Statistical analysis was 
performed with commercially available software (IBM SPSS statistics, version 20.0 
for Windows; SPSS, Chicago, IL, USA). Figures were performed using GraphPad 
Prism 6 for Mac OS X ver. 6.0b, Graph-Pad Software, Inc., San Diego, CA, USA.
Results
Demographic data and clinical characteristics
A total of 280 patients were analyzed in our NPSLE clinic and 204 fulfilled the ACR 
classification criteria for SLE. [22, 23]  In 112 SLE patients, the NP complaints were 
better explained by another cause. A NPSLE syndrome involving the CNS was 
diagnosed in 92 (45.1%) of the SLE patients. Among the patients diagnosed with 
CNS NPSLE, 144 different ACR NP syndromes were established. Thirty-four patients 
had at least one diffuse NPSLE syndrome while 63 patients were diagnosed with 
at least one focal NPSLE syndrome according to the ACR 1999 NPSLE definitions. 
[25] Five patients were diagnosed with both focal and diffuse symptoms. Patient 
demographics relevant to the present study are shown in Table 1. A description of 
all CNS syndromes included in the study is shown in Table 2. 
Relationship of anti-C1q antibodies and C1q CIC and SLE and NPSLE
Using the recommended cut-off values by the manufacturer, the positivity rates of 
anti-C1q levels and C1q CIC in HC were 13.5% (27 of 200) and 19.5% (39 of 200), 
respectively. Prevalence of anti-C1q antibodies and C1q CIC in NPSLE and SLE 
patients is shown in Table 1. Levels of anti-C1q antibodies were higher in patients 
with NPSLE than in both SLE (median 16.9 versus 8.0; P < 0.05) and HC (16.9 
versus 7.0; P < 0,001) (Figure 1A). The same trend was seen in the C1q CIC levels 
when SLE and NPSLE were compared with HC (Figure 1B). 
As previously described by other authors , the prevalence of anti-C1q antibodies 
was significantly higher in SLE patients with renal involvement (OR=2.1, 95% CI 1.1–
3.9, P < 0.05), positivity for anti-dsDNA (OR=5.1, 95% CI 2.6–9.7, P < 0.001), and 
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anti-Sm antibodies (OR=5.9, 95% CI 1.8–19.2, P < 0.001). [3, 27, 28] We also found 
a higher prevalence of C1q CIC in SLE patients with renal involvement (OR=2.1, 
95% CI 1.1–3.9, P < 0.05), positivity for anti-dsDNA (OR=3.8, 95% CI 2.1–7.4, P < 
0.001), and anti-Sm antibodies (OR=4.9, 95% CI 1.5–15.9, P < 0.05). The titers of 
anti-C1q antibodies and C1q CIC were also correlated with the SLEDAI-2K scores 
(P < 0.001 and P < 0.05, respectively) (data not shown). Among NPSLE subsets, 
anti-C1q antibodies were significantly elevated only in diffuse NPSLE compared 
Table 1. Comparison clinical data SLE and NPSLE 
 SLE 
n = 112 
NPSLE 
  Total 
n = 92 
Focal * 
n = 63 
Diffuse * 
n = 34 
Age, mean ± SD years 44.01 ± 13:78 40 ± 13.68 a 43.23 ± 13.86 33.21 ± 10.19 b,d  
Sex, no. female/male 99/13 82/10 55/8 32/2 
Age at diagnosis SLE, mean ± SD years 35.4 ± 14.93 32.45 ± 14.8 35.01 ± 15.98 26.34 ± 10.05 a,c 
SLE disease duration, mean ± SD years 8.61 ± 8.55 7. 83 ± 8.31 8.23 ± 8.7 7.57 ± 8.08 
SLEDAI-2K  4 [0 – 19] 6 [0 – 22] b 6 [0 – 22] b 9 [0 – 22] b,c 
ACR 1982 criteria for SLE † 
    Malar Rash 54 (48.2) 34 (37) 21 (33.3) 15 (44.1) 
    Discoid rash 25 (22.3) 12 (13) 9 (14.3) 4 (11.8) 
    Photosensitivity 50 (44.6) 31 (33.7) 22 (34.9) 9 (26.5)
    Oral ulcers 40 (35.7) 32 (34.8) 19 (30.2) 14 (41.2)
    Arthritis 79 (70.5) 63 (68.5) 41 (65.1) 26 (76.5) 
    Serositis 30 (26.8) 30 (32.6) 22 (34.9) 11 (32.4) 
    Renal disorder 33 (29.5) 19 (20.7) 9 (14.3) 12 (35.3) c 
    Neurologic disorder 8 (7.1) 25 (27.2) a 14 (22.2) 12 (35.3) 
    Hematologic disorder 50 (44.6) 44 (47.8) 29 (46) 17 (50) 
    Immunologic disorder 78 (69.6) 71 (77.2) 49 (77.7) 26 (76.5) 
    Positive ANA 111 (99.1) 89 (96.7) 61 (96.8) 32 (94.1) 
Autoantibodies and complement † 
    aCL IgG 8 (7.1) 27 (29.3) b 21 (33.3) b 7 (20.6) a 
    aCL IgM 6 (5.4) 8  (8.7) 6 (9.5) 3 (8.8) 
    LAC 19 (17) 43 (46.7) b 35 (55.5) b 12 (35.3) a,c 
    Anti-β2GP1 IgG †† 6 (5.4) 17 (18.5) a 13 (20.6) a 5 (14.7) 
    Anti-β2GP1 IgM †† 2 (1.8) 5 (5.4) 5 (7.9) 1 (2.9) 
    Antinuclear antibody 75 (66) 78 (84.8) a 53 (84.1) a 29 (85.3) a 
    Anti-dsDNA 23 (20.5) 33 (35.9) a 22 (34.9) a 14 (41.2) a 
    ENA 66 (58.9) 48 (52.2) 32 (50.8) 20 (58.8) 
    Anti-SSA/Ro52 57 (50.9) 30 (32.6) a 21 (33.3) a 11 (32.4) a 
    Anti-SSB/La 19 (17) 8 (8.7) 5 (7.9) 4 (11.8) 
    Anti-RNP 12 (10.7) 18 (19.6) 11 (17.5) 8 (23.5) 
    Anti-Sm 4 (3.6) 12 (13) a 7 (11.1) 6 (17.6) a 
    C1q low 7 (6.3) 13 (14.1) 7 (11.1) 8 (23.5) a 
    C3 low 29 (25.9) 42 (45.7) a 24 (38.1) 22 (64.7) b,c 
    C4 low 27 (24.1) 30 (32.6) 14 (22.2) 18 (52.9) a,c 
    CH50 25 (22.3) 37 (40.2) a 19 (30.2) 19 (55.9) b,c 
    AP50 16 (14.3) 27 (29.3) a 14 (22.2) 16 (47.1) b,c 
    Anti-C1q high 34 (30.3) 41 (44.6) a 26 (41.3) 17 (50) a 
    C1q CIC high 43 (38.4) 40 (43.5) 27 (42.9) 15 (44.1) 
Antiphospholipid syndrome 
    APS diagnosis 4 (3.6) 22 (23.9) b 26 (41.3) b 6 (17.6) a 
    Arterial thrombosis ever 19 (17) 48 (52.2) b 43 (68.3) b 7 (20.6) d 
    Vascular thrombosis ever 6 (5.4) 15 (16.3) a 13 (20.6) a 3 (8.8) 
aCL: anticardiolipin antibodies; ACR: American College of Rheumatology; ANA: antinuclear antibody; LAC: Lupus anticoagulant; NPSLE: neuropsychiatric SLE; 
SLE: systemic lupus erythematosus; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000. 
* 5 patients were included in both groups 
† Number and percentage per group 
†† Only available in 150 (69/81) patients 
a. P < 0.05 when compared with SLE 
b. P < 0.001 when compared with SLE 
c. P < 0.05 when compared with focal SLE 
d. P < 0.001 when compared with focal SLE 
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with the rest of SLE patients (20.8 versus 8.7; P < 0.05) or HC (20.8 versus 7; 
P< 0.05). No differences in levels were found for C1q CIC when SLE and NPSLE 
patients where compared. Among the different NPSLE syndromes, only headache 
showed a significantly higher prevalence of anti-C1q antibodies (OR=4, 95% CI 
1.1–14.6, P < 0.05). No significant associations were found between individual 
NPSLE syndromes and C1q CIC.
Central nervous system NPSLE syndromes 
Aseptic meningitis 1 
Cerebrovascular disease 45 
Demyelinating syndrome 1 
Headache 11 
Movement disorder 3 
Transverse myelitis 6 
Seizure disorder 12 
Psychosis 11 
Acute confusional state 3 
Anxiety disorder 5 
Cognitive disorder 28 
Mood disorder 18 
Diffuse vs. focal NPSLE syndromes 
Focal NPSLE * 63 
Diffuse NPSLE ** 34 
Diffuse NPSLE without non-specific syndromes † 61 
Focal NPSLE without non-specific syndromes †† 22 
NPSLE: neuropsychiatric systemic lupus erythematosus; SLE: systemic 
lupus erythematosus.  
a. Possible > 1 NPSLE syndrome per patient 
* Focal neuropsychiatric-SLE: Aseptic meningitis, cerebrovascular 
disease, demyelinating syndrome, headache, movement disorder, 
transverse myelitis, seizure disorder. 
** Diffuse neuropsychiatric-SLE: psychosis, acute confusional state, 
anxiety disorder, cognitive disorder, mood disorder.  
† Non-specific diffuse NPSLE syndromes: mood disorder, anxiety and 
mild cognitive dysfunction. 
†† Non-specific focal NPSLE syndromes: headache. 
Table 2 Central nervous system NPSLE syndromesof patients included in the study (n=92)a
CH50 and AP50 and NPSLE 
NPSLE patients showed significantly lower CH50 values (78.1 versus 89.8; P < 
0.05) (Figure 2A) and AP50 (55.8 versus 69.8; P = 0.001) than SLE patients (Figure 
2B). When the different NPSLE subgroups were analyzed, the levels of CH50 and 
AP50 were markedly lower in patients with diffuse NPSLE (both P < 0.001) when 
compared with SLE patients. No differences were found for focal NPSLE. We 
next examined the association between CH50 and AP50 with the different NPSLE 
syndromes. As shown in Figure 3, psychosis (OR=60, 95% CI 7.2–501, P < 0.001), 
headache (OR=5, 95% CI 1.4–18.3, P < 0.05), seizure (OR=6, 95% CI 1.7–20.9, P < 
0.05) and cognitive dysfunction (OR=3.8, 95% CI 1.5–9.8, P < 0.05) had significantly 





















































Figure 1. Serum titers of A anti-C1q antibodies and B C1q CIC in 92 consecutive patients with NPSLE, 
112 patients with SLE and 200 HC. The titers of anti-C1q antibodies were significantly higher in patients 
with NPSLE than in the rest of SLE patients and HC (P < 0.05 and P < 0.001, respectively). For anti-
C1q antibodies and C1q CIC we indicate with a broken line the cut-off value recommended by the 
manufacturer. Horizontal lines indicate median. C. Receiver-Operating-Characteristic (ROC) curves for 
the levels of anti-C1q and C1q-CIC in 112 patients with SLE and 92 patients with NPSLE. The mean (± 
SE) area under the curve for anti-C1q (continuous line) was 0.61 ± 0.04 and for C1q-CIC (dashed line) 
was 0.56 ± 0.04 for predicting NPSLE. 
HC: healthy controls; NPSLE: neuropsychiatric systemic lupus erythematosus; SE: standard error; SLE: 
systemic lupus erythematosus. 
Kruskal-Wallis test with Dunn’s multiple comparison test and Mann-Whitney’s U test, *P < 0.05, ** P < 




















































higher prevalence of low AP50 when compared with SLE, while psychosis (OR=9.2, 
95% CI 2.2–37.6, P = 0.001), cognitive dysfunction (OR=3.4, 95% CI 1.5–8.2), P < 
0.05) and mood disorder (OR=3.5, 95% CI 1.2–9.7, P < 0.05) showed a significantly 
higher prevalence of low CH50. No significant associations were seen with other 
individual NPSLE syndromes. 
























Figure 2. Measurement of the activation state of the A classical pathway (CH50) and B alternative 
pathway (AP50) in 92 consecutive patients with NPSLE and 112 patients with SLE. For CH50 and AP50 
we indicate with a broken line the cut-off value used in our laboratory. The levels of both CH50 and AP50 
were significantly lower in NPSLE patients than in SLE (P < 0.05 for CH50 and P < 0.001 for AP50). 
Horizontal lines indicate mean. 
NPSLE: neuropsychiatric systemic lupus erythematosus; SLE: systemic lupus erythematosus. 
One-way analysis of variance test, *P < 0.05, ** P < 0.01
Circulating levels of C1q, C3 and C4 in relation to NPSLE
A significantly higher prevalence of low C3 was shown in NPSLE (OR=2.4, 95% 
CI 1.3–4.3, P < 0.05), and especially in diffuse NPSLE patients (OR= 5.2, 95% CI 
2.3–11.9, P < 0.001), when compared with SLE patients (Figure 3). An association 
between NPSLE patients and lower values of C4 and C1q was not found; however 
low levels of these components were more prevalent in  diffuse NPSLE (C4: OR= 
3.5, 95% CI 1.5–7.8, P < 0.05; C1q: OR= 4.6, 95% CI 1.5–13.8, P < 0.05). No 
associations were found with focal NPSLE. Patients with lupus psychosis showed 
higher prevalence of low C1q (OR=5, 95% CI 1.5–15.8, P < 0.05), C3 (OR=28.6, 
95% CI 3.5–230.4, P < 0.001) and C4 (OR=3.8, 95% CI 1.1–13.3, P < 0.05) when 
compared with SLE. Patients with cognitive dysfunction showed also higher 
prevalence of low C1q (OR=5, 95% CI 1.5–15.8, P < 0.05), C3 (OR=4.4, 95% CI 
1.8–10.5, P < 0.001) and C4 (OR=3.6, 95% CI 1.5–8.6, P < 0.05) when compared 
with SLE. An association between headache and higher prevalence of low C4 
(OR=3.7, 95% CI 1.1–13.3, P < 0.05) was also found. No significant associations 
were seen with other individual NPSLE syndromes. 
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Figure 3. Odds ratios and 95% confidence interval analyzing the association of the more common 
NPSLE presentations in patients 204 SLE patients from the Leiden NPSLE-clinic. A. Anti-C1q high as 
considered by manufacturer (> 20 U/ml), B. C1q CIC high as considered by the manufacturer (> 4.4 
µg Eq/ml), C. low C1q measured  using laser nephelometry (< 102 mg/l), D. low C3 measured using 
laser nephelometry (< 0.9 g/l), E. low C4 measured using laser nephelometry (< 95 mg/l), F. low AP50 
measured using functional assays (< 39%), and G. CH50 measured using functional assays (<74%). 
NPSLE: neuropsychiatric systemic lupus erythematosus. 
χ2 test and Fisher exact tests.
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Complement activation and complement components as predictor of NPSLE
When possible complement activating factors were included in the model, NPSLE 
patients showed a positive significant association with aCL IgG (OR=3.126, 95% 
CI 1.2–7.8, p < 0.05), LAC (OR=3.233, 95% CI 1.6–6.5, p = 0.001) and AP50 
(OR=0.985, 95% CI 0.975–0.996, p < 0.05) after controlling for age, anti-dsDNA, 
anti-Sm, anti-C1q and CP50. When complement components were included in the 
model aCL IgG and LAC remained significant. After using all the same potential 
predictors, only aPL IgG (OR=5.974, 95% CI 2.1–17.3, P < 0.001), LAC (OR=5.765, 
95% CI 2.6–12.6, P < 0.001), and also C4 (OR=4.175, 95% CI 1.4–12.2, P < 0.05) 
remained significantly associated with focal NPSLE. After adjusting for above 
listed covariates, diffuse NPSLE was associated with a lower age (P < 0.05). 
When complement components were included in the model, C3 was significantly 
associated with diffuse NPSLE (OR=3.552, 95% CI 1.4–8.5, P < 0.05). Furthermore, 
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when complement activation instead of complement components were used in the 
model, AP50 was also significantly associated with diffuse NPSLE (OR=0.972, 95% 
CI 0.957–0.988, P < 0.001). When SLEDAI-2K was included in the model we missed 
these two associations.
Discussion
The pathogenic processes that lead to damage or dysfunction in the nervous 
system due to SLE remains poorly understood. Important associations have 
been reported between several autoantibodies and nervous system involvement 
in SLE, such as aPL and cerebrovascular disease and anti-ribosomal P and 
lupus psychosis. However, no specific autoantibodies have been identified and 
serological biomarkers for NPSLE are extremely needed. The role played for other 
elements beyond autoantibodies in the NPSLE pathogenesis remains unclear. [29, 
30] This study analyzes for the first time the serum complement components (C1q, 
C3 and C4), complement activation (CH50 and AP50), anti-C1q and C1q CIC in 
a large and well defined cohort of NPSLE with CNS involvement. The results in 
the present study have disclosed that none of the complement elements studied 
is useful to differentiate between NPSLE and SLE, but that some of them may be 
associated with a certain subset of NPSLE patients.
We found an association between a low C4 and focal NPSLE. Complement 
activation is known as an important mechanism of tissue injury in cerebral ischemia. 
Platelets bearing the complement activation product C4d are a known link between 
cerebrovascular inflammation and thrombosis. Moreover, they have been proposed 
as a specific biomarker for SLE diagnosis, and a relation with NPSLE has also been 
suggested. [31, 32] An increase in deposition of complement activation products, 
such as C4d, on platelets is associated with the presence of LAC, aCL and anti-
β2GP1 antibodies and it has been proposed as an essential mechanism in aPL-
mediated thrombosis in SLE. [12, 13, 31, 32] Serum hypocomplementaemia is 
commonly seen in patients with primary APS, reflecting complement activation 
and consumption. [33] It has been suggested that aPL may activate monocytes 
and macrophages via anaphylatoxins produced in complement activation. [33] An 
increase in complement activation products in serum of aPL positive patients has 
been related with the development of transient ischemic events and stroke. [34] In 
our cohort, the focal NPSLE group was characterized by a higher prevalence of aPL 
and APS. [35] We have demonstrated that in this group the association with a low 
serum C4 was due to the association with the presence of LAC and aPL IgG. Serum 
C4 was not independently associated with focal NPSLE or with cerebrovascular 
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disease in SLE patients.
Diffuse NPSLE patients were associated with a markedly low AP50 and low C3. 
Furthermore, we have shown for the first time that higher levels of anti-C1q antibodies 
are significantly associated with this NPSLE subgroup when compared with SLE. 
Complement components C3 and C4 are recognized markers of global SLE activity 
and CH50 and AP50 are markedly reduced during SLE flares. [1, 36] As reported in 
previous reports, we also observed an association between anti-C1q antibodies and 
known markers of global SLE activity such as SLEDAI-2K, anti-dsDNA antibodies, 
C1q CIC, C3, C4 and CH50. [27, 37, 38] Furthermore, similarly to other authors, we 
also confirmed a relation between anti-C1q levels and lupus nephritis [39, 40] and 
younger age [28]. Whereas in murine studies the association between anti-C1q 
autoantibodies and lupus nepthritis has been wel established [41, 42], no such 
data is available to support the role of anti-C1q in other organ SLE manifestations. 
Diffuse NPSLE manifestations have been linked to higher global SLE activity. [7] In 
our cohort we corroborate this association. We also miss the association between 
AP50 and low C3 and diffuse NPSLE when SLEDAI-2K is included in the model. 
Since there is no gold-standard for NPSLE, we cannot exclude the possibility that 
the multidisciplinary team that attributed the NP complaints to SLE was influenced 
by hypocomplementaemia when taking into account disease activity, which may 
explain our results. However, in clinical practice only hypocomplementaemia and not 
the evaluation of individual complement components have been taken into account. 
The fact that only AP50 and C3 and not CP and C4 were related with diffuse NPSLE 
is intriguing and may be not biased by concomitant disease activity, leading us 
to make further interpretations. In murine models of lupus cerebritis, targeted and 
selective inhibition of the alternative complement pathway has been shown to be 
effective. [14-18] We could hypothesize that the complement alternative pathway 
may play a role in the pathogenesis of patients with diffuse NPSLE. 
Among the NPSLE syndromes, patients with lupus psychosis had markedly higher 
complement activation and a higher prevalence of low serum C1q, C3 and C4. This 
association was especially marked for AP50 and C3. Lower serum C3 levels have 
been seen in corticosteroid-induced psychosis [43] and corticosteroid-induced 
psychiatric diseases [44] in SLE patients. In the last case, C1q and C4 were also 
seen to be lower, however only serum C3 level was an independent risk factor for 
new-onset of psychiatric disorder after corticosteroid therapy. [45] Interestingly, 
complement activation was increasingly linked to schizophrenia development and 
psychopathology. [46] Some authors have reported lower levels of serum C3 in 
schizophrenia patients when compared with HC [47] whereas others have observed 
higher levels of C3 in these patients. [48] Also at the molecular level, the gene 
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encoding C3, has been reported to be a genetic schizophrenia susceptibility region 
[49] , whereas others could not confirm this. [50] In SLE patients data is limited. 
Pego-Reigosa et al. reported low C3 levels in 4/10 patients with lupus psychosis 
and no other complement alterations were found. [51] Watanabe et al. reported 
lower serum C3 levels in NPSLE patients; however patients with lupus psychosis 
had higher serum C3 levels than other NPSLE patients. [52] Further research on the 
link between alternative pathway and psychosis in patients with and without SLE, 
taking into account other factors such as corticosteroid treatment, is warranted.
Complement components C1q and C3 have emerged in the last years as key 
mediators of synaptic elimination and connectivity during development, normal 
ageing and neurodegeneration. [53-55] Complement has been localized at 
synapses and mediates pruning of synapses through a C3-dependent microglial 
phagocytosis process. [56] Cognitive decline, mediated through synapse elimination, 
has become a recognized feature in several neurodegenerative diseases. [57] 
For example, recent data in multiple sclerosis, an immune mediated inflammatory 
disease characterized for demyelination and leading memory impairment in up to 
65% of patients, support that in the hippocampus of these patients there were clear 
signs of activation of complement components C1q-C3. [58] This disease shares 
some similarities with NPSLE patients. [59] In our cohort, we found significantly 
lower levels of complement components, including C1q and C3, in patients with 
cognitive dysfunction due to SLE. The functional relationship between activation 
of complement components in brain pathology of NPSLE patients should be 
investigated.
Although measuring complement activation by evaluating consumption of serum 
C3 and C4 are regularly used to track disease activity in SLE, the interpretation of 
these levels is challenging. They are acute phase reactants that may not decrease 
until late in a SLE flare. [60] Alterations in several components of the complement 
system in human CSF in NPSLE patients have been scarcely studied. Higher levels 
of C3 and C4 have been reported in CSF when compared with controls. It has 
been proposed that this may reflect an intrathecal compensatory production [9]. 
Intrathecal activation of terminal complement by measuring SC5b-9 in NPSLE 
patients has also been seen. [11] Recent studies have demonstrated that several 
complement components are synthesized in the CNS [61] and also in human 
neuronal cells in vitro. [62] Autoantibodies in SLE are supposed to form immune 
complex with complement [63] and induce neuroinflammation, but how this process 
occurs is far from clear. 
Our study has notable limitations. Complement split products, which may reflect 
more accurately complement activation, were not evaluated. Furthermore, since 
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lumbar puncture is not routinely performed in all the patients included in the NPSLE-
cohort, we lack the results of complement components in CSF. Determination of 
complement split products and parallel analysis of CSF must be included in future 
studies. Another limitation of our study is the retrospective design. On the other 
hand, all NPSLE patients were unselected, consecutive patients, diagnosed in the 
same institution and in the same standardized multidisciplinary procedure. Our 
future work is aimed at prospectively finding associations between complement 
activation and components. Due to referral nuances, immunosuppressive therapy, 
including in some cases methylprednisolone, was already started in a few patients 
with diffuse NPSLE patients. The effect of the therapy, mainly methylprednisolone, 
on complement component levels was not investigated. The small number of NPSLE 
patients per syndrome may affect the power in this study and must be mentioned as 
a limitation. Definite conclusions concerning the relationship between complement 
components and NPSLE syndromes cannot be drawn. 
To our knowledge, this study is the first to investigate associations between 
complement elements measured in serum and clinical and serologic parameters 
in a large NPSLE cohort. No association was found between anti-C1q or C1q CIC 
when all the NPSLE patients where compared with SLE. We found an association 
between diffuse NPSLE and anti-C1q, decreased C3 and AP50 and focal NPSLE 
and decreased C4. These associations found between certain NPSLE subgroups 
and several complement elements may be explained due to other factors such 
as aPL in the case of focal NPSLE and global disease activity in the case diffuse 
NPSLE. The roles of several complement aspects, especially alternative pathway 
activation and C3, in lupus psychosis and cognitive dysfunction merits further 
research. 
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Abstract
C1q is the initiation molecule of the classical pathway of the complement system 
and is produced by macrophages and immature dendritic cells. As mast cells 
share the same myeloid progenitor cells, we have studied whether also mast cells 
can produce and secrete C1q.  
Mast cells were generated in vitro from CD34+ progenitor cells from buffy coats or 
cord blood. Fully differentiated mast cells were shown by both RNA sequencing 
and qPCR to express C1QA, C1QB and C1QC. C1q produced by mast cells has a 
similar molecular make-up as serum C1q. Reconstituting C1q depleted serum with 
mast cell supernatant in haemolytic assays, indicated that C1q secreted by mast 
cells is functionally active. The level of C1q in supernatants produced under basal 
conditions was considerably enhanced upon stimulation with LPS, dexamethasone 
in combination with IFN- γ or via FcεRI triggering. Mast cells in human tissues 
stained positive for C1q in both healthy and in inflamed tissue. Moreover, mast cells 
in healthy and diseased skin appear to be the predominant C1q positive cells.
Together, our data reveal that mast cells are able to produce and secrete functional 
active C1q and indicate mast cells as a local source of C1q in human tissue. 
Introduction
Mast cells (MCs) are immune cells that are important in the first line of defence and 
are predominately present in tissues that are close to host/environment interfaces, 
like the skin and mucosal surfaces. MCs are important in host defence, innate and 
adaptive immunity, tissue homeostasis and immune regulation [1-3]. As effector 
cell in disease, MCs are well known for their anaphylactic effects in allergy. MCs 
are also described to play a role in other diseases like atherosclerosis, contact 
dermatitis, cancer and arthritis [4-7].
MCs can be activated via IgE receptor (FcεRI) cross-linking, resulting in 
degranulation of the MCs, but they can also be activated via other pathways. 
These pathways include activation via the C3a and C5a receptors resulting in 
degranulation, secretion of cytokines, chemokines and bioactive lipids [8, 9]. 
C1q is the first complement component in the classical pathway of the complement 
system [10]. Together with C1r and C1s it forms the C1 complex. C1q plays a 
prominent role in the clearance of immune complexes and by binding to apoptotic 
and necrotic cells and it can facilitate phagocytosis [11-13]. The interaction of C1q 
with immunoglobulins is of importance to protect against infections but it may also 
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contribute to tissue damage by targeting self-tissue [14].
The main producers of C1q have been reported to be macrophages and immature 
dendritic cells [15-18]. Also other studies have reported that other non-macrophage-
like cells are able to produce C1q like trophoblast cells [19]. MCs are differentiated 
from the same myeloid precursor cells that can also give rise to macrophages and 
dendritic cells [20]. We have investigated whether also MCs can produce and 
secrete functionally active C1q as this would imply MCs to have a role in tissue 




CD34+ hematopoietic stem cells were isolated from either peripheral blood 
mononuclear cells or from mononuclear cells present in cord blood. Mononuclear 
cells were isolated from buffy coats (Sanquin, The Netherlands) or cord blood 
using Ficoll-Paque density gradient centrifugation. CD34+ hematopoietic stem 
cells were isolated from the PBMC’s with CD34+ microbeads (Miltenyi Biotec, 
The Netherlands). The isolated CD34+ stem cells were differentiated into MCs by 
culturing the cells in culture medium as described before [21]. Heparinized cord 
blood was obtained through the department of Obstetrics of the Leiden University 
Medical Center (Leiden, The Netherlands), in accordance with the Declaration 
of Helsinki. CD34+ cells isolated from cord blood were cultured as described 
previously [22] [23]. After 8-9weeks the purity of the MCs was determined using 
Flow Cytometry, whereby CD117 (c-kit), FcεRI and CD203c were measured. 
ELISA
MCs were cultured in a cell concentration of 2*106 cells/mL for 72h either in 
medium alone, or stimulated to increase C1q levels with LPS (Sigma, 200 ng/
ml), Dexamethasone (Pharmacy LUMC, Leiden, The Netherlands, 10 µM) + IFN-γ 
(Peprotech, 200 U/mL). For FcεRI triggering, the MCs were sensitized with hybridoma 
IgE (non-immune, BPD-DIA-HE1-1, Enzo, Life Sciences, 0.1 µg/ml) overnight. Next, 
the MCs were washed to remove soluble IgE and activated using goat anti-human 
IgE (Nordic-MUbio, Susteren, The Netherlands, 10 µg/ml). Subsequently, culture 
supernatants were harvested and analysed by ELISA to determine C1q levels as 
described before [24].
IL-8 production was evaluated using the human IL-8 ready-set-Go!® (2nd 
generation) ELISA (eBioscience). 
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Haemolytic reconstitution assay
MCs were cultured for 72 with or without LPS (200 ng/ml). After 72h, The supernatant 
was harvested and used for a haemolytic reconstitution assay. Antibody opsonized 
sheep erythrocytes were prepared in sucrose containing veronal buffer and 
incubated with C1q-depleted serum (Quidel) diluted in veronal gelatin containing 
buffer and different dilutions of MC supernatant or different concentrations purified 
C1q (Quidel) as a positive control and as a negative control culture medium with or 
without LPS was used. After incubation the amount of lysis was measured compared 
to total lysis (sheep erythrocytes together with saponine and water) at 412 nm. The 
amount of lysis is corrected to medium control [25].
qPCR of C1qA, C1qB and C1qC
RNA was isolated from cultures mast cells after 7-8 weeks of cultured. The qPCR 
was performed as described previously [24]. Relative mRNA expression was 
calculated using the reference gene RPL5. The qPCR products were analyzed on a 
2% agarose gel and visualized with Nancy 520 (Sigma). 
Sequencing
RNA was isolated from cord blood derived mast cells (CBMC) from three independent 
donors. RNA was paired-end sequenced with Illumina Hiseq 2000, aligned to Hg38 
human genome reference. Read were quantified per gene and RPKM (Reads Per 
Kilobase per Million) levels were calculated using EdgeR (as previously described 
Suurmond et al) [26].
Western blot analysis of C1q
Using western blot the composition of C1q was examined by detection of the three 
chains of the C1q protein. Supernatants of stimulated and unstimulated MCs were 
used in reduced and non-reduced SDS conditions. The western blot was performed 
using previously described methods [24].
ß-hexosaminidase release assay
In this assay the MCs were sensitized with IgE as described above in a cell 
concentration of 0.5 x 106 cells/ml in an 96-wells plate on 37°C/ 5% CO2. The 
next day, the cells were washed with Tyrode’s buffer to clear unbound IgE and 
stimulated with mouse anti-human IgE or with compound 48/80 (Sigma, 50 µg/
ml) for 15 minutes or with buffer only as a control. Triton-X100 (1%) was used as 
indicator of 100% degranulation. After incubation the supernatant was incubated 
at 37°C with substrate (2 mM 4-Nitrophenyl N-acetyl-b-D-glucosaminide, Sigma 
N9376). The reaction was stopped using stop solution (0.2 M Glycine, pH 10.7) 
after 1-hour incubation and extinction was measured at 405 nm. 
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Immunofluorescence staining on cytospins and human tissue
For the detection of C1q positive MCs in tissues, paraffin embedded skin tissue, 
psoriatic skin and synovial tissue of rheumatoid arthritis (RA) patients (5µm) was 
used. After treating the slides via standard methods to deparaffinise, tryptase 
and C1q were visualized using mouse anti-tryptase (Millipore) and rabbit anti-
C1q (DAKO) or matching isotypes for 1 hour at RT. After washing the detection 
antibodies goat anti-rabbit ALEXA488 (Invitrogen) and donkey anti-mouse 
ALEXA568 (Invitrogen) were added to the slides for one hour at RT. After incubation 
the slides were washed and dried. Finally, the slides were covered with Vectashield 
containing DAPI (Vector laboratories) to stain nuclei and analysed on a Zeiss Axio 
ScopeA1 microscope and on a Confocal microscope (Leica SP8 confocal). Using 
cytospins, cultured MCs were pelleted onto poly-lysine coated microscope slides 
(Thermo scientific/Menzel-Glaser) in a cell concentration of 50.000 cells/slide and 
stained for immunofluorescence with minor adjustments. All participants in the 
study provided informed consent and the study was approved by the local medical 
ethics committee.
Stained sections were randomly analysed of three different slides per condition. 
The mean number and standard deviation in percentages of single- and double-
positive cells in 10 high-power fields (magnification 400x) was scored blindly by 
three observers.
Statistical analysis
Statistical analysis on the ELISA data was performed using a Wilcoxon signed rank 




Cultured MCs spontaneously produce functionally active C1q 
Mast cells were in-vitro differentiated from CD34-positive precursors. After 7-8 
weeks of culture, the purity of the MCs population was determined by staining for 
CD117 (c-kit), FcεRI and CD203c, and was shown to range from 90% to 98% (Figure 
1A). The expression of the mRNA’s encoding the three C1q chains by unstimulated 
MCs was analysed by PCR. We could detect the expression of C1QA, C1QB and 
C1QC, all required to generate a functional C1q molecule (Figure 1B). With qPCR 
we analysed expression level of C1qA in PBMCs and MCs. Here we observe that 
PBMCs have a higher RNA expression level of C1qA compared to MCs (Figure 1C). 
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The expression of mRNA was confirmed using sequencing RNA extracted from 
CBMC. The RPKM values indicate that the expression of C1q genes in CBMCs are 
relatively high with an RPKM value >100 and only a 3 fold lower expression than the 
household gene RPL5. These data provide additional and independent evidence 
that at basal levels C1q is expressed by MCs (Figure 1D). Additionally, expression of 
C1q related genes were analysed on unstimulated CBMCs using RNA sequencing. 
This analysis demonstrates that MCs express several  C1q receptors (Table 1). The 
C1q associated serine proteases C1r and C1s and also the inhibitor C1-INH show 
a low expression in CBMCs (Table 1).   
To demonstrate that MCs are able to produce C1q, we performed a sandwich-
ELISA for C1q using culture supernatant obtained from MCs cultures. In a time 
frame of 72 hours unstimulated MCs are able to secrete C1q as C1q was readily 
detectable in culture supernatants; mean 11.34 ng/ml; range 3.08-24.6 ng/ml (Figure 
1E). To further confirm that mast cells produce C1q and to rule out the possibility 
that a few contaminating cells would be responsible for the C1q mRNA and C1q 
protein observed, we next performed a cytospin of cultured cells and analysed the 
presence of intracellular C1q. As depicted in figure 1E, all cells stained positive 
for tryptase (Figure 1F). In addition also a staining for C1q revealed that all cells 
stained positive for C1q compared to isotype controls (Figure 1F). This indicates 
that not contaminating cells but rather MCs are responsible for C1q production. 
Using western blot analysis we observed that C1q secreted from unstimulated 
MCs derived from either peripheral blood and cord blood contain all three C1q-
polypeptides. These polypeptides display the same size as compared to C1q 
present in NHS (C1qA: 28 kDa, C1qB: 25 kDa, C1qC: 24 kDa). Likewise, the size 
of the secreted C1q protein is identical to C1q from NHS (Figure 1G). These results 
indicated that MCs are able to produce and secrete a complete C1q protein.
Next, we wished to examine whether C1q secreted by MCs is functionally active 
and is able to restore the activity of the classical pathway in C1q-depleted serum. 
Therefore we used a reconstitution experiment based on a haemolytic assay for the 
classical pathway. Antibody opsonized sheep erythrocytes were incubated with 
C1q depleted serum to which we added either buffer, unconditioned culture medium 
or culture medium in which mast cells had been cultured for three days. Whereas 
incubation with C1q depleted serum did not result in lysis of erythrocytes a limited 
degree of lysis was observed when culture supernatant of unstimulated mast cells 
was used. A substantial lysis was observed when culture supernatant of mast cells, 
stimulated with LPS to increase the C1q production, was used (Figure 1H). Overall 
these data demonstrate  that C1q produced by mast cells is functionally active. 
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Figure 1. Production of C1q by cultured MCs.
A. Representative flow cytometric plots of characterization of MCs after 8-9 weeks of culture using 
CD117, CD203c and FcεRI staining on the cell surface. Histograms gated on live cells on forward 
scatter (FSC) and side scatter (SSC) Open histograms represents isotype controls, closed histograms 
represents the stainings. B. qPCR products from unstimulated MCs were analysed on a 2% agarose gel. 
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C1q production is upregulated after MC stimulation but does not correlate with 
IL-8 production or degranulation
We next wished to determine whether stimulation of MCs by triggers other than LPS 
could also alter C1q production by MCs. For this purpose, we stimulated MCs with 
LPS, DXM + IFN-γ or α-IgE for 72 hours. DXM in combination with IFN-γ are well-
known stimulations to increase the C1q production in myeloid cells as described 
before for THP-1 derived macrophages [27]. All triggers enhanced C1q production 
as detected in culture supernatants harvested after 72 hours of stimulation (Figure 
2A-C). Similar results were obtained using cord blood derived MCs (Figure 2D). 
However, IL-8 production, a prototype chemokine released by MCs was not 
increased upon triggering of MCs with DXM + IFN-γ (Figure 2E), indicating that C1q 
and IL-8 production are differentially regulated upon this stimulation.
MCs are well-known for their ability to release granules, containing different 
compounds e.g. ß-hexosaminidase, tryptase, chymase and histamine [28]. 
Gene Conventional name Mean RPKM ±SD
C1QA C1qA 137.5 39.4
C1QB C1qB 210.5 45.1
C1qC C1qC 104.8 23.8
C1R C1r 1.5 0.6
C1S C1s 5 0.8
SERPING1 C1-INH 1.8 1
C1QBP gC1qR 89.3 38.8
CALR cC1qR 484 190.8
ITGB1 CD29 63.8 13.2
ITGA2 CD49B 4.5 1.7
LAIR1 CD305 15.5 7
Table 1. Gene expression 
levels of complement 
components in unstimulated 
CBMCs expressed in 
Reads Per Kilobase per 
Million (RPKM)
As positive control for C1qA, C1qB and C1qC DXM + IFN-γ stimulated PBMCs were used. RPL5 is used 
as housekeeping gene. C. Relative mRNA expression of C1qA in PBMCs and MCs. Data is relative to 
the house keeping gene RPL5 (N=1). D. Gene expression profile of C1q from three independent cord-
blood derived mast cell donors. X axis depicts the three genes of C1q as well as RPL5. On the Y-axis, 
gene expression levels in reads per kilobase per million (RPKM) are depicted. E. C1q production during 
a time course  of 72h (set at 100%) was analysed by ELISA (N = 6 different MCs donors). F. Cytospin 
staining of tryptase and DAPI together with matching isotype control of C1q (Rabbit Ig, ALEXA 568) 
on cultured peripheral MCs (400x magnification) and a of C1q and DAPI with matching isotype control 
of tryptase (Ms IgG1, ALEXA 568) on cytospins (400x magnification). Scale bars indicates 50 µm. G. 
Reduced and non-reduced supernatant of cultured MCs from peripheral blood and from cord blood was 
analysed on western blot. H. Haemolytic reconstitution assay of the classical pathway by adding MC 
supernatant to C1q depleted serum with the % heamolysis compared to a 100% lysis control as read-out 
(N=3) expressed as mean and standard deviation. As a positive control purified C1q ranging from 3,7 
ng/ml to 300 ng/ml was used.
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Figure 2. C1q production upon stimulation of MCs.
A. C1q production measured by ELISA in the supernatant of stimulated peripheral MCs for 72 h with 
LPS. B. DXM + IFN-γ. C. α-IgE. D. Stimulation of cord blood derived MCs with α-IgE. E. IL-8 ELISA on 
supernatant of peripheral MCs (N=3) after stimulation with LPS, DXM+IFN-γ and α-IgE. F. Percentages 
ß-hexosaminidase and C1q release assay after 15 min incubation of α-IgE defined by total release with 
Triton X100. G. Percentages ß-hexosaminidase and C1q release after 15 minutes of stimulation with 
compound 48/80 defined by total release with Triton X100.
Therefore we were interested whether C1q is released after MC degranulation. 
To this end, we performed a degranulation assay, by stimulating the cells via the 
FcεRI or compound 48/80, two well-known triggers for degranulation [29, 30]. As a 
marker of degranulation we measured the release of ß-hexosaminidase next to C1q. 
Following FcεRI triggering for 15 minutes, ß-hexosaminidase was readily detected 
in the supernatants, whereas only a low level of C1q was present. (Figure 2F). 
However, after stimulation with compound 48/80 for 15 minutes a different pattern 
was noted as a secretion of 40% of C1q is seen (Figure 2G). These observations 
suggest that C1q is present in preformed vesicles of MCs and is released upon 
compound 48/80 triggering. 
A B C D
E F G
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Figure 3. Distribution of C1q positive MCs in different tissue.
A. C1q and tryptase staining on healthy skin analysed on a conventional fluorescence microscope 
(upper images, 1000x magnification, scale bar is 10 µm) and on a confocal microscope (lower images, 
digital zoom 3000x magnification, scale bar is 3,3 µm). B. C1q and tryptase staining on psoriatic skin 
and on RA synovium (conventional microscope, 1000x magnification, scale bar is 10 µm). C. single 





C1q production by human mast cells | 117
6
C1q producing MCs are present in various tissues 
ToW determine whether MCs present in tissue are positive for C1q we performed an 
immunofluoresence staining on healthy skin tissue using tryptase as a MC marker. 
As shown in figure 3A, tryptase positive MCs also express C1q as detected by 
immunofluorescence (Figure 3A), indicating that also tissue resident MCs express 
C1q (C1q positive MCs 91% ± 5%).
MCs have been indicated to play a role in several diseases. We wished to analyse 
whether MCs in diseased tissue express C1q. To this end, psoriatic skin and 
synovial tissue from RA patients was analysed for the presence of C1q positive 
MCs. As shown in figure 3B, all tryptase expressing cells in psoriatic skin are also 
positive for C1q (C1q positive MCs 98% ± 2%), resembling our observations made 
in the healthy skin. Likewise, in synovial tissue, tryptase positive MCs expressing 
C1q were present. However, in contrast to healthy and psoriatic skin, not all 
tryptase positive cells expressed C1q (C1q positive MCs 37% ± 3%). Moreover, 
also tryptase negative cells expressing C1q are observed in RA synovial tissue, 
indicating the presence of other C1q positive cells like macrophages and dendritic 
cells  (Figure 3C). 
As shown in figure 2G C1q is released via degranulation. As shown in Figure 3A-C, 
C1q is stained in a granular pattern in all C1q positive mast cells in different tissues.
Together, these results indicate that tissue-resident mast cells, analysed directly ex 
vivo in healthy skin, psoriatic skin and synovial tissue, stain positive for C1q, and in 
particular in the skin, are the main cell C1q-positive cell subset. 
Discussion
Macrophages and immature dendritic cells have been described as the main 
producers of C1q [15, 16]. Because MCs are derived from myeloid precursors cells, 
which also give rise to macrophages and dendritic cells, we wished to determine 
if MCs are able to produce C1q.  Here, we demonstrate that unstimulated MCs 
produce and secrete functional C1q. Moreover, our data show that C1q production 
by mast cells can be modulated by several immune stimuli. The amount of C1q 
produced by mast cells (mean 11.34 ng/ml; range 3.08-24.6 ng/ml) is lower 
compared to published values of macrophages (64.6  ng/mL;  range,  2-148 ng/
control for C1q (green), double staining C1q (green), tryptase (red) on RA synovium. Conventional 
fluorescence microscope, 400x magnification. Scale bar is 50 µm D. Quantified percentages in 10 high 
power fields (HPF) of C1q positive mast cells in healthy skin (N=3), psoriatic skin (N=3) and RA synovium 
(N=3) expressed in mean and standard deviation. 
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mL, after 48h culture)  and dendritic cells (318.4  ng/mL;  range,  100-679  ng/mL, 
after 48h culture) [15] and also as compared to our own analysis (data not shown).
To investigate if the secretion of C1q is differently regulated from secretion of 
cytokines produced by MCs, we compared IL-8 secretion, a prototype cytokine 
produced by MCs, with C1q secretion after stimulation. We observed that stimulation 
of MCs by LPS and FcεRI cross-linking induced both C1q- and IL-8 release 
whereas stimulation by DXM + IFN-γ induced only C1q secretion. These results are 
intriguing as they suggest that C1q and IL-8 production are differentially regulated 
and that C1q production is also boosted in situations that MCs are not primed for 
IL-8 production. It is conceivable that this is important in the case of, for example, 
apoptotic cell clearance. C1q can bind to apoptotic cells and promote ingestion 
of apoptotic cells by macrophages [12, 13, 31]. The clearance of apoptotic cells 
is of particular importance in tissues, where apoptosis is abundant because of 
normal tissue turnover/homeostasis such as in the skin. In this process, infiltration 
of inflammatory cells would not be desirable. MCs producing C1q can contribute 
to this process to maintain tissue homeostasis by the production of C1q without 
the concomitant production of inflammatory cytokines. We did not observe a clear 
effect of C1q stimulating MCs (data not shown).
Another possible role of C1q is promoting wound healing. As shown in mouse 
studies, C1q  can be deposited on endothelial cells, leading to the enhancement 
of permeability, tube formation and angiogenesis [32]. It is conceivable that also 
under these conditions, the release of inflammatory cytokines is not beneficial and 
that C1q produced by MCs contributes to angiogenesis and normal tissue repair in 
situations where the production of inflammatory cytokines is less desired. 
In our ELISA analysis we observed a spontaneous production of C1q by unstimulated 
MCs. Likewise, in human tissue we observed a granular type of staining of C1q 
in MCs suggesting that C1q is also present in the granules of the MCs. Indeed, 
degranulation using compound 48/80 led to an increase in C1q release, which 
coincided with the release of ß-hexosaminidase in supernatants suggesting that 
C1q can also be produced upon granule release. Furthermore, we did not obtain 
any evidence that C1q is expressed on the cell surface of MCs (data not shown).
In the immunofluorescence staining of C1q positive mast cells is a granular pattern 
seen. In addition of production of C1q by mast cells, another feature what we have 
to take into account is the possibility of the uptake of C1q from the extracellular 
milieu and store them in granules [33]. 
A limitation of this study is the lack of an in vivo model to define the role of C1q 
produced by MCs in healthy and disease conditions as mouse MCs do not appear 
to produce C1q. Using an ELISA, we could not detect C1q in the supernatant of 
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bone marrow derived mouse MCs after the same stimulation as used for the human 
MCs. In the same assay, we did detect C1q in the supernatant of bone marrow 
derived macrophages and dendritic cells from the mouse (data not shown). It is 
therefore difficult to translate our results using human cells and tissue in an animal 
model for further studies aiming to analyse in vivo relevance.
Together,  we show that MCs are able to produce and secrete functionally active 
C1q and that MCs in healthy and in diseased human tissue are positive for C1q. 
Our findings suggest that C1q from MCs could have a previously unrecognized 
contribution in several processes such as inflammation, clearing of immune 
complexes, apoptotic and necrotic cells. Especially in human skin, tryptase 
positive cells are the most abundant C1q expressing cells which makes it tempting 
to speculate that C1q produced by MCs is playing an important role in tissue 
homeostasis and defence. 
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Abstract
Chondrocytes, the cellular constituents of cartilage, play an important role in the 
cartilage by producing extracellular matrix molecules. During inflammation both 
chondrocytes and cartilage can be damaged. Previous studies have shown that 
chondrocytes express mRNA encoding for C1q. This is surprising as it is currently 
unclear what the role of such a large molecule is in the cartilage. In this study we 
demonstrate that C1q is produced and secreted by chondrocytes.
Using western blot and ELISA we analysed the presence of C1q in cultured 
chondrocytes. By stimulation with pro-inflammatory cytokines we examined the 
changes in mRNA expression of matrix molecules and of C1q. 
Ex-vivo isolated human chondrocytes express mRNA for the three C1q chains. 
Cultured primary chondrocytes stain positive for C1q and secrete C1q into the 
culture supernatant. Upon stimulation with pro-inflammatory cytokines, the C1q 
mRNA expression is upregulated. Staining human cartilage sections for C1q 
revealed that in-situ chondrocytes are positive for C1q.
In this study we demonstrate that C1q can be produced and secreted by 
chondrocytes under basal conditions, which can be enhanced by pro-inflammatory 
stimuli. 
Introduction
Chondrocytes are the only cells present in the healthy cartilage matrix. They 
are responsible for the synthesis and turnover of the extracellular cellular matrix 
(ECM). Chondrocytes are round cells originating from mesenchymal stem cells that 
represent 5-10% of the cartilage volume located in matrix cavities called lacunae. 
The two major ECM macromolecules produced by chondrocytes are collagen type 
2 and aggrecan [1].
The complement system is an important part of the innate immune defence, which 
is able to kill pathogens and remove dying cells and immune complexes. The 
complement system can be activated via three pathways; the classical pathway, 
the lectin pathway and the alternative pathway. C1q is the recognition molecule 
of the classical pathway and together with the proteases C1r and C1s it forms 
the C1 complex. C1q can activate the classical pathway by binding different 
ligands such as IgG and IgM antibodies, but also DNA, C-reactive protein (CRP) 
and lipopolysaccharides [2-4]. C1q producing cells are mainly originating from 
the haematopoietic stem cells, such as macrophages, immature dendritic cells 
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and mast cells [4-7]. However, other reports suggest that trophoblasts, decidual 
endothelial cells, microglia and osteoclasts can also produce C1q [8-10]. 
Previously studies describe that matrix molecules like aggrecan, fibromodulin and 
osteoadherin are able to bind C1q and are able to activate the classical pathway 
of the complement system [11-13]. The cartilage oligomeric matrix protein (COMP) 
is a strong ligand for C1q, but it is hypothesised that COMP interferes with the 
binding site of C1r and C1s resulting in inhibition of the classical pathway [14]. This 
interference is also applies to the cartilage fragments decorin and biglycan [15]. 
Based on these interesting interactions between C1q and several matrix molecules 
the question arises if C1q is actually present inside the cartilage.
Proteomic data from synovial fluid from osteoarthritic patients shows the presence 
of complement components. Wang et al described that complement is important 
in the pathogenesis of osteoarthritis [16], as the presence of the MAC could be 
detected on cartilage.  Although the authors speculate that complement activation 
takes place outside the cartilage and then attacks damaged chondrocytes, it 
cannot be excluded that chondrocytes initiate complement activation leading to 
MAC deposition takes place in the cartilage [16]. Similarly, In the early 90’s it was 
already described that cartilage is positive for the mRNA for C1q and that deposits 
of the C1q molecule were present in the cartilage, but the source and function of the 
production of C1q was not clear [17]. 
Therefore, we have investigated whether primary human chondrocytes are able 
to produce and secrete C1q and if the production can be modulated under 
inflammatory conditions such as present in OA.
Materials and methods
Patients 
Cartilage was obtained as left-over tissue from total knee-replacement surgery 
performed on OA patients in the Alrijne hospital, Leiden, The Netherlands. The local 
medical ethical committee approved the study.
Isolation of chondrocytes
Chondrocytes were isolated from cartilage obtained from total knee-replacement 
surgery. Cartilage pieces were incubated with pronase (2 mg/ml, Roche) for 
1,5 hours, followed by overnight incubation with collagenase type 2 (225 U/ml, 
Worthington). After digestion, chondrocytes were directly lysed for western blot 
analysis or RNA isolation. The purity of the chondrocytes was determined using 
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Flow Cytometry, whereby CD14 (APC) and CD45 (FITC) were measured using a 
BD LSRFortessa cell analyser (BD Biosciences, San Jose, CA, USA) and analysed 
using FlowJo v10.1 software (Tree Star, Ashland, OR, USA).
Stimulation of chondrocytes
Primary chondrocytes were plated in a cell concentration of 5*105 cells/mL in 
F12 DMEM culture medium (Gibco) supplemented with 10% BSA (Bovine Serum 
Albumin), L-glutamine, penicillin and streptomycin. Chondrocytes were stimulated 
for 24 hours with IL-1ß (30 ng/ml, R&D systems), TNF-α (100 ng/ml, R&D systems), 
TGF-ß (10 ng/ml, peprotech) or LPS (100 ng/ml, Sigma). After stimulation RNA 
isolation was performed. For western blot analysis primary chondrocytes were lysed 
and C1qA, C1qB, C1qC was determined as previously described [18]. Culture 
supernatants of unstimulated chondrocytes were harvested after 72h and analysed 
by ELISA to determine C1q levels as described before [18].
qPCR
RNA was isolated from cultured chondrocytes using RNeasy mini kit (Qiagen) 
and analysed with the NanoDrop (NanoDrop Technologies). Subsequently, the 
RNA was treated with DNase I, Amplification Grade (Invitrogen) and cDNA was 
synthesized using superscript III (200U/µl, Invitrogen). The cDNA was diluted 1:25 
and qPCR was performed using SensiFast Sybr no-ROX (Bioline) and primers with 
a start concentration of 10 pmol. Primers specific for MMP1, collagen type 1,type 2, 
type 10, C1r, C1s, C3, C5 and the C1q genes C1qA/B/C, as well as the reference 
RPL5 were used (see table 1 for primer sequences). The qPCR was performed on 
the real time PCR system (BioRad CFX-384) with an activation step of 3 min on 95°C 
(hot start polymerase activation), a melting temperature of 95°C for 5 seconds and 
an annealing temperature of 64°C for 5 seconds followed by an elongation step for 
20 seconds on 72°C for 40 cycles. At the end of the protocol melting curves were 
performed from 65°C to 95°C  to test specific binding of SensiFast Sybr. The qPCR 
for the C1q genes was performed with annealing temperatures ranging from 58-
65°C for 10 seconds. 
Immunofluorescence staining of C1q in chondrocytes
Freshly isolated chondrocytes were cultured on poly-d-lysine (Sigma 50 µg/ml) 
chamber slides (Thermo Scientific) and fixated using 1% paraformaldehyde and 
acetone. Cells were subsequently incubated with rabbit anti-C1q (DAKO) or isotype 
control rabbit Ig (DAKO) for 1 hour at RT. After washing, slides were incubated with 
goat anti-rabbit ALEXA 488 (Invitrogen) and ActinRed 594 (Applied bioprobes) for 
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Gene 5’ Forward 3’ Reverse
MMP1 CTGGCCACAACTGCCAAATG ATTCTGTCCCTGAACAGCCC
Collagen type 1 CATGTTCAGCTTTGTGGACCTC ATGGTACCTGAGGCCGTTCT
Collagen type 2 TCCTAAAGGAGCCCGAGGTGCC CAGGAGCTTGGAGGCCGGGTT









Table 1. qPCR primers
1 hour at RT. Finally, the slides were covered with Vectashield containing DAPI 
(Vector laboratories) to stain nuclei and analysed on a confocal microscope (Leica 
SP8 confocal). 
Immunohistochemical staining of C1q in cartilage
 C1q was detected on paraffin embedded cartilage of OA patients (5µm). Slides 
were deparaffinised and stained with 10 µg/ml rabbit anti-C1q (DAKO) or matching 
isotype control for 1 hour at RT . Next, slides were incubated with anti-rabbit HRP for 
1 hour at RT and were analysed on a Zeiss Axio ScopeA1 microscope. 
Results
Chondrocytes are able to produce and secrete C1q
Primary human chondrocytes were isolated and the purity of the isolated 
chondrocyte population was analysed using flow cytometry. As shown in figure 
1A, chondrocytes are negative for the hematopoietic marker CD45 and the myeloid 
marker CD14, indicating no contamination of cells from hematopoietic or myeloid 
origin (Figure 1A). 
Next, we investigated whether chondrocytes can produce and secrete C1q. Using 
western blot analysis we detected C1q in chondrocyte lysates from 2 OA patients 
(Figure 1B). We found the molecular size of C1q in the chondrocytes to be similar to 
the C1q band observed in the lysates of PBMCs and Normal Human Serum (NHS) 
(positive controls). No C1q was observed in the lysate of T cells (negative control). 
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Using confocal microscopy we observed C1q inside the cultured chondrocytes 
(Figure 1C). We confirmed the data by ELISA on lysates of unstimulated 
chondrocytes cultured for 72 hours (Figure 1D). Moreover, secretion of C1q into 
the culture supernatant could be shown in one out of 2 OA patients (Figure 1D). 
To confirm that chondrocytes express C1q in the natural environment of cartilage, 
we performed an immunohistochemical staining on OA cartilage. Also staining of 
the human cartilage showed positivity for C1q, which is mainly located around the 
nucleus of the chondrocytes (Figure 2A-C). 
Figure 1. Chondrocytes are positive for C1q.
A. Flow cytometry of chondrocytes isolated from human cartilage compared to PBMCs, B. Western 
blot analysis of lysates of cultured chondrocytes (72 hours, N=2), CD4 T-cells and PBMCs. As positive 
control NHS is used, C. Cultured chondrocytes on chamber slides. C1q is visualized with ALEXA488. 
Actin is used as counterstaining at 594 nm. The nucleus is stained with DAPI, 630x magnification, the 
scale bars indicates 6.3 µm, D. C1q ELISA on lysates and supernatants of cultured chondrocytes (72h). 
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Figure 2. The expression of C1q in human cartilage. A. Expression of C1q (HRP) with a co-staining 
of haematoxylin with a magnification of 400x, B. With a 1000x magnification. C. Isotype control on 400x 
magnification.
mRNA expression of C1q is increased in a pro-inflammatory environment
Next, we wished to determine the mRNA expression pattern of C1qA, C1qB and 
C1qC by qPCR. We investigated the basal expression pattern as well as the 
changes that occur after stimulation with cytokines that are relevant for OA [19]. 
Stimulation with IL-1ß and TNFα led to an increased expression of C1qA, C1qB and 
C1qC (Figure 3A-C). Furthermore, we investigated whether the expression of other 
complement components could be modulated by these inflammatory cytokines. 
Expression levels of C1qA, C1qB and C1qC were upregulated by IL-1ß and TNFα 
stimulation, while no or limited enhancement was observed for stimulation with 
TGF-ß and LPS (Figure 3). The expression pattern of the serine protease C1r and 
C1s and of complement component C3 was largely comparable to the C1q genes, 
with the exception that LPS did induce a modest increase in their expression after 
24 hours of stimulation (Figure 4A, C), while C5 was unaffected by any of the studied 
cytokines. LPS had little or no effect on the complement genes we studied (Figure 
4D).
As a positive control for TGF-ß stimulation we determined the mRNA expression of 
Collagen type 1, 2 and 10. As expected TGF-ß increases the expression of Collagen 
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Figure 3. mRNA fold change of C1q genes after 24 hours stimulation (N=3). A. Fold change 
expression after correction for RPL5 of C1qA, B. C1qB, C. C1qC. Data represents mean and SEM of 3 
different OA donors measured in duplicate.
Figure 4. mRNA fold change of complement components after 24 hours stimulation (N=3). A. Fold 
change expression after correction with RPL5 of C1r, B. C1s, C. C3. D. C5.  Data represents mean and 
SEM of 3 different OA donors measured in duplicate.
type 1 (figure 5A) [20], while it had little effect on type 2 and type 10 (Figure 5B,C). A 
small decrease of the expression of Collagen type 1, type 2 and 10 was seen after 
stimulation with IL-1ß., while TNF or LPS stimulation had little or no effect on the 
collagen gene expression. MMP1 expression was determined as a positive control 
for the pro-inflammatory stimulations and shows an increase after stimulation of IL-
1ß, TNFα and LPS (figure 5D). The pattern of up/down regulation of the C1q genes 
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Figure 5. mRNA fold change of chondrocyte components after 24 hours stimulation (N=3). A. Fold 
change expression after correction with RPL5 of Collagen type 1, B. Collagen type 2, C. Collagen type 
10. D.  MMP1.  Data represents mean and SEM of 3 different OA donors measured in duplicate.
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The main producers of C1q are originating from haematopoietic stem cells. 
Chondrocytes are originating from the mesenchymal stem cell and are important 
in the production of extracellular matrix molecules to build up the cartilage. Wang 
et al have described that the dysregulation of complement in the synovial joints in 
has a central role in the pathogenesis of osteoarthritis [16]. In the early 90’s it was 
demonstrated that the cartilage was positive for several complement components 
like C1q on RNA level, but the presence of C1q could not be shown in vitro. Also the 
function or relation with the cartilage was not described [17]. Here, we demonstrate 
that chondrocytes are able to produce and secrete C1q and that the production of 
C1q is increased by cytokines present in osteoarthritic joints and believed to play a 
role in disease pathogenesis.
To evaluate which factors could modulate the production of C1q by chondrocytes 
we stimulated the chondrocytes with cytokines that are known to be present in 
the joint during inflammation [19]. Stimulation with IL-1ß and TNF-α showed an 
increase in mRNA expression of C1q compared to unstimulated chondrocytes. 
Furthermore, the expression patterns of the C1q genes were different compared to 
the expression of the collagen genes, which are of importance in the maintenance 
of the cartilage, as seen after TGF-ß stimulation where the gene expression of 
collagen types 1,2 and 10 were upregulated and the expression of the C1q genes 
were downregulated. C1q released by chondrocytes could deposit on cartilage 
or synovium which is damaged by inflammation however, C1q is a large (460kD) 
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molecule and the size limit of proteins that can move freely in cartilage is estimated 
to be around 65 kD [17]. Therefore it is likely that C1q produced by chondrocytes 
must serve a local rather than a systemic function. Conceivably, C1q would function 
in an autocrine setting in stimulating the chondrocyte or alternatively C1q would be 
involved in local complement activation, involving C1r and C1s directly outside the 
chondrocyte. We speculate that C1q and complement activation may be involved 
in maintenance of a lacuna for the chondrocyte.
Previous studies have demonstrated that the serine protease C1s can degrade 
collagen type 1 and type 2 when it is activated [21] and that it can play a role in 
the degenerative cartilage matrix in RA [22]. In our results we also see an increase 
of RNA expression of C1s and for C1r after stimulation. This could indicate that in 
pro-inflammatory conditions complement activation will occur in the cartilage or 
at the surface of the cartilage. Together with the production of C1q and C3 it is 
highly conceivable that the production of different complement components by 
chondrocytes plays a role in the degradation of the cartilage.
In our study we only used cartilage and chondrocytes derived from patients 
who underwent a total knee replacement due to osteoarthritis, indicating that the 
cartilage is already in inflammatory conditions. In further investigations the role 
of complement in cartilage it would be interesting to compare these results with 
healthy donors. 
In conclusion, our results indicate that chondrocytes are able to produce and secrete 
C1q, suggesting a previously unexpected role of this molecule in the cartilage.
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Summary and discussion
In this thesis we report on the production of C1q by immune cells and non-immune 
cells. Deficiency of C1q as a consequence of a genetic mutation is strongly 
associated with the development of Systemic Lupus Erythematosus (SLE). In 
chapter 2 we describe a not previously reported genetic mutation in one of the 
C1q genes. The patient is currently a teenager and has suffered from infectious 
problems but did so far not develop SLE. When patients are diagnosed with C1q 
deficiency due to a genetic mutation the risk to develop SLE is high, but there is 
high degree of variation between the patients in clinical manifestations. In chapter 
3, we used questionnaires to get an overview of C1q deficient patients worldwide, 
revealing that once the C1q deficient patients reach adulthood that then the chance 
of fatal infections is reduced. This overview highlighted the importance of a personal 
approach for therapy, especially in young children.  
A mutation in of the genes of C1q can also lead to a non-functional structure of C1q, 
Low Molecular Weight-C1q (LMW-C1q). In chapter 4 we described a C1q deficient 
patient who has low levels of LMW-C1q. This patient demonstrates a severe form 
of SLE and neuropsychiatric SLE (NPSLE). Our data indicate that the classical 
pathway activity is not required for NP involvement in SLE, but the absence of C1q 
and the biological consequences may have a role in the pathogenesis of NPSLE.
When we investigated other NPSLE patients we see many different clinical 
manifestations. To investigate if complement activation and components play a role 
in NPSLE we performed data analyses and serum analyses. The NPSLE patients 
have a high degree of complement activation and the levels of anti-C1q and C1q 
circulating immune complexes are increased compared to healthy controls. The 
association NPSLE and the levels of anti-C1q, C3/AP50 and C4 are probably due 
to the disease activity and the presence of anti-phospholipid antibodies (discussed 
in chapter 5).
In the second part of this thesis we described the production of C1q by different 
cells. We demonstrate that mast cells, which are originating from the same myeloid 
progenitor cells as the already known C1q producing cells; macrophages and 
dendritic cells, are able to produce functional active C1q (chapter 6). We were able 
to detect C1q secreted from chondrocytes. This was surprising as these cells are 
originating from mesenchymal stem cells, which is different from haematopoietic 
stem cells. The main role of chondrocytes is to produce cartilage and maintain the 
homeostasis of the cartilage (chapter 7).
Overall, all these studies demonstrate the involvement of C1q in disease and the 
production of C1q by immune cells and non-immune cells. 
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The role of C1q in disease
In our institute we have identified a C1q deficient patient with a previously unknown 
mutation in the C1qB chain of C1q resulting in a complete C1q deficiency. Several 
studies have already shown the association between the absences of C1q in disease 
like SLE [1-3]. However, this patient did demonstrate several infections but no signs 
of autoimmunity. Currently, he is receiving prophylactic antibiotics to protect the 
patient from bacterial infections. If and when patients with a C1q deficiency will 
develop lupus is unpredictable and it is therefore important to keep him under close 
control to detect any signs of autoimmunity as early as possible.
Because C1q deficiency is often reported in literature as case reports describing 
only the initial presentation and no follow-up, we investigated the clinical 
manifestations of C1q deficient patients around the world. Our data shows that 
even during follow up the clinical presentation and severity of symptoms in persons 
that are deficient for C1q is very divers. Even though this case series comprised 
45 individuals (comprising the majority of cases known to date) there is no clear 
algorithm to describe how to manage C1q deficiency clinically. Also differences in 
clinical presentation are seen within families with the same mutation in one of the 
C1q genes. Indicating, that other factors like environmental factors or epi-(genetic) 
changes can influence the different outcome of clinical presentations [4, 5]. From 
this study we can conclude that the manifestation of the disease in C1q deficient 
patients is unfortunately not predictable. Especially in young children, where the 
risk of developing a fatal infectious disease is high. In future studies C1q deficient 
patients should be monitored regularly from a young age if possible. Together 
with the familial history and clinical manifestations of the C1q deficient patient, the 
clinician can decide which treatment will be applied, like FFP or HSCT.
Patients with established SLE have a wide diversity in clinical presentations. 
Patients can e.g. demonstrate cutaneous lupus or glomerulonephritis, but can also 
demonstrate symptoms involving the nervous system resulting in neuropsychiatric 
SLE (NPSLE). In the literature neuropsychiatric involvement in patients with a 
deficiency in the early components of the classical pathway is only described 
for patients with a C1q deficiency. We have had the opportunity to investigate in 
detail a C1q deficient patient demonstrating NPSLE.  With this study together with 
literature research we suggest that the classical pathway activity is not required 
for NP involvement in SLE but the absence of C1q and subsequently some of its 
biological functions may have a role in the pathogenesis of NP-SLE.
Typical phenomena in SLE are B-cell hyper activation, production of autoantibodies 
and formation of immune complexes [6, 7]. Since immune complexes activate 
complement a state of secondary complement deficiency can develop. The role 
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of C1q and other complement components in NPSLE is not exactly known.  Due 
to the complexity of the disease no specific biomarkers are known for NPSLE. As 
anti-C1q antibodies are very common in SLE patients we measured the presence of 
anti-C1q antibodies and also the presence of C1q circulating immune complexes in 
serum of a large cohort of NPSLE patients. As previous studies have reported, the 
levels of anti-C1q in NPSLE patients is higher compared to healthy controls. These 
high levels of anti-C1q antibodies correlated with the SLE activity. Unfortunately no 
association of the presence anti-C1q antibodies and NSPLE patients compared 
with SLE patients is found, indicating that anti-C1q is not a useful biomarker that can 
be used to identify NPSLE patients. Furthermore, in NPSLE patients complement 
activation is taking place, which is seen as decreased levels of C1q and C3 but 
this is probably the result of the presence of autoantibodies that form immune 
complexes. 
C1q production by immune and non-immune cells
The production and secretion of complement factors by immune cells is of importance 
in case of local infection or local processes such as clearance of immune complexes 
or apoptotic cells. In this thesis we demonstrate that mast cells are able to produce 
and secrete functionally active C1q. This could be of importance in maintaining the 
homeostasis of tissues were mast cells are abundant, like in the synovial tissue of 
joints affected by arthritis [8, 9]. In infections mast cells can be of importance due 
to degranulation and/or the release of IL-8, which is an important chemokine that 
attracts other immune cells. When mast cells are stimulated with LPS or via FcεRI 
triggering the mast cells release IL-8 and also C1q. The release of C1q can have a 
role by activating the complement system resulting in attracting more immune cells 
due to the cleavage products C3a and C5a [10, 11]. Another role that could be of 
importance in the release of C1q by mast cells is the clearance of apoptotic cells, 
macrophage polarization or stimulating cytokine production [12-14].
Previous studies have described a role for C1q in different inflammatory tissues [15, 
16]. Like in RA patients the haemolytic activity is up-regulated in synovial fluid as a 
consequence of complement activation and due to genetic variations in and around 
the C1q genes, the levels of C1q are increased in RA patients [15, 17]. C1q is 
predominantly acting in the clearance of apoptotic cells, macrophage polarization 
or stimulating cytokine production [13, 14, 18]. Several studies demonstrated that 
C1q is able to bind to cartilage fragments of which could be of importance in the 
pathogenesis of joint disease. Interference of C1q with the cartilage oligomeric 
matrix protein (COMP), decorin and biglycan will result in an inhibition of complement 
activation [19, 20]. On the other site, aggrecan, fibromodulin and osteoadherin are 
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also able to bind to C1q and enhance the activation of the classical pathway [21-
23]. C1q produced by mast cells can play a role in the complement activation in 
synovial tissue. When mast cells are activated and secrete C1q, the activation of 
complement can be either dampened or enhanced by binding of certain cartilage 
fragments. More interestingly is that not only immune cells in the joint are able to 
produce C1q [24]. In our study we demonstrate that chondrocytes have also the 
capability to produce C1q. This is quite remarkable, because chondrocytes are 
originating from mesenchymal stem cells compared to dendritic cells, macrophages 
and mast cells, which are from haematopoietic origin. The production of C1q by 
chondrocytes was already described in 1996 [25], but the exact role and the 
regulation of secretion was not described. We show in our study that non-stimulated 
chondrocytes are able to produce C1q and that the production is increased after 
stimulation of pro-inflammatory cytokines including IL-1ß. Also the proteases C1r 
and C1s had the same mRNA expression pattern as the C1q genes. Compared 
to the expression of collagen the C1q genes and C1r and C1s expression pattern 
were opposed. Why chondrocytes produce C1q should be further investigated, 
due to the high molecular weight of C1q (460 kD) it is unable to diffuse through the 
cartilage of which the maximum 65 kD is [25]. 
Perspectives
The involvement of the complement system in inflammation has been studied for 
many years. Especially the role of complement on cell development, attraction and 
differentiation is well studied by different research groups [26-28]. Remarkably, 
the clinical relevance and physiological importance is not yet well understood. 
Ricklin et al reviewed in 2010 the importance of complement in the maintenance 
of the homeostasis [29]. For example in normal pregnancy, C1q plays a key role 
in trophoblast invasion, spiral artery remodelling and the normal placentation [30]. 
The sources of C1q in the maternal tract are trophoblasts and decidual endothelial 
cells (DECs) [24]. In mouse studies it is shown that C1q -/- mice were unable to 
clear apoptotic trophoblasts resulting in an accumulation of apoptotic trophoblasts 
and an abnormal placentation. These mice showed features of preeclampsia 
like hypertension, albuminuria, endotheliosis, less placenta vascular endothelial 
growth (VEGF), an increase of soluble VEGF receptor 1 (sFlt-1) and oxidative 
stress. Furthermore, decreased blood flow, increased fetal death, diminished litter 
size, abnormal invasion of trophoblasts and increased levels of STAT-8 (inhibitor 
trophoblast migration) [31]. Unfortunately, this is all based on mouse studies and 
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no literature is known about pregnancy in women with C1q deficiency. In our 
questionnaires no problems with pregnancy were described. However, since half 
the cohort was male and different age groups were present, such an effect could 
easily have been missed. Apparently C1q is of major importance in pregnancy and 
therefor it would be of importance and interesting to know if there are problems with 
pregnancy in C1q deficient women. 
Another important role for C1q is the role in synaptic pruning [32]. During 
developmental stage the neural network is growing continuously leading to excessive 
synaptic formation, which needs to be under control to maintain a proper functioning 
of the central nervous system (CNS). The role of C1q in this stage is to contribute to 
the elimination of synapses during developmental stages of the CNS. This process 
is also well studied in mice. C1q -/- mice have aberrant synaptic connectivity and 
show forms of epilepsy, which is probably a result of excessive excitatory synapses 
[33, 34]. Also this phenomenon is not observed in our questionnaires. The clinicians 
treating C1q deficient patients describe no epilepsy or other CNS abnormalities. 
However, in the literature NPSLE symptoms are described in patients with a C1q 
deficiency in previous studies[3, 35-38]. For future research it would be interesting 
to find out if there is an association with C1q deficiency and the development of 
NPSLE. Due to absence of C1q in the brain during the developmental stage, the 
synaptic connectivity could also be aberrant as in C1q -/- mice leading to NPSLE 
events during aging.
A standard treatment for C1q deficiency is not available. Most of the patients 
receive immunosuppressive drugs or are receiving fresh frozen plasma (FFP) on 
a regularly basis [39, 40]. Another therapy, which is more radical, is hematopoietic 
stem cell transplantation (HSCT). Already 2 patients are treated successfully after 
HSCT. Following HSCT, the levels of C1q in serum are in the normal range and they 
are cured from SLE [41, 42]. Because there are people with C1q deficiency that 
live a normal life without any infections or symptoms of autoimmunity the question is 
raised if those people should also undergo a HSCT, because the chance to develop 
SLE is almost 100%. If the patient is feeling healthy and does not have signs of 
autoimmunity it may not be ethical to perform HSCT, because it will be ‘cutting 
in a healthy body’. Also one patient, who underwent HSCT to normalize the C1q 
levels in the serum, died of multiorgan failure and an intracerebral hemorrage. For 
the clinicians treating C1q deficiency patients it should be important to check the 
patient on a regular basis and to determine if the patient is vulnerable to infections 
in his surroundings. An infection will trigger the immune system, which can also 
be a trigger the development of SLE. An extra consideration the clinicians should 
make is to vaccinate the patient with additional vaccinations like, Pneumococcus, 
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Meningococcus, Hepatitis B and the seasonal influenza vaccinations next to the 
regular childhood vaccines such as measles, diphtheria, tetanus and poliomyelitis.
As described before the role of complement in the human body is diverse. The 
complement system and especially C1q can be involved in many processes. 
C1q can be involved in the induction of angiogenesis and tissue repair. In mouse 
studies C1q is believed to be a unique player in the angiogenesis and thereby be 
a potential therapeutic target in wound healing of the skin [43]. In this study they 
demonstrate that C1q will bind to the endothelial cells by their globular head and 
without activating the complement system will induce an angiogenic phenotype 
in endothelial cells. The suggested source of C1q is probably plasma, but by 
analysing our data we can consider that the mast cells in the skin are a source of 
C1q production as the mast cells in the skin are the most abundant C1q positive 
cells. Vascular endothelial growth factor (VEGF) plays a major role angiogenesis 
and mast cells are an important source of VEGF. This together will suggest that C1q 
producing mast cells have a potential role in inducing an angiogenic phenotype in 
endothelial cells and thereby promote vascularization.
Angiogenesis is a phenomenon that also takes plays in the bone repair [44-46]. 
For example, chondrocytes are able to produce VEGF and mice lacking the VEGF 
gene in chondrocytes have an impaired embryonic bone development, reducing 
angiogenesis and reduced removal of terminally differentiated hypertrophic 
chondrocytes [47-49]. In the mouse studies they suggested gC1qR on the 
endothelial cells as potential receptor of C1q inducing the angiogenic phenotype of 
the endothelial cells. In a study in 2012 it is also demonstrated that chondrocytes are 
positive for gC1qR [50]. This could indicate that C1q produced by chondrocytes can 
regulate a feedback loop to chondrocytes by binding to gC1qR and subsequently 
induce VEGF resulting in the survival of the chondrocytes.  When C1q is produced 
by chondrocytes C1r and C1s are also produced. These proteases are able to 
degrade collagen, which is an important matrix molecule [51, 52]. This is also an 
indication that C1q and other complement components could be of importance 
in the survival of chondrocytes. C1q, C1r and C1s can bind matrix molecules 
surrounding the chondrocytes and subsequently degrade the collagen to maintain 
the lacunae.
In diseased joints as in rheumatoid arthritis (RA) and in osteoarthritis (OA) higher 
levels of complement components are detected in the synovial fluid. As described 
by Wang et al more deposition of MAC is found on the cartilage of osteoarthritic 
joints [16]. Together with our findings and with the findings of Bradley et al, who 
described that chondrocytes are positive for C1q [25], we can suggest that C1q 
produced by chondrocytes can play a role in the pathogenesis of OA and maybe 
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also in RA. However, the major source of C1q is possibly C1q from the circulation 
that deposits on the cartilage due to damage by pro-inflammatory cytokines. So the 
additional value of C1q producing chondrocytes should be investigated.
Conclusion
In this thesis the combination of epidemiological research of C1q deficient patients 
and NPSLE patients in combination with cell biology of C1q producing cells is 
described. This combination provides more insight into how C1q producing cells 
can play a role in autoimmune diseases like SLE, NPSLE, RA and OA. 
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Het molecuul C1q speelt een belangrijke rol in de homeostase van het menselijk 
lichaam. Het wordt voornamelijk geproduceerd door immature dendritische cellen 
en macrofagen.
Zonder C1q hebben individuen een verschuiving binnen hun immuunsysteem, 
waardoor ze een verhoogd risico op infecties hebben maar ook daardoor een 
auto-immuunziekte kunnen ontwikkelen. Tot nu toe zijn dergelijke C1q-deficiënte 
patiënten vooral per individu beschreven betreffende de mutaties van het C1q gen 
en de klinische presentatie. 
In de studies beschreven in dit proefschrift hebben we in detail gekeken naar 
twee individuele C1q deficiënte patiënten maar ook naar de variabele klinische 
presentatie van een groot aantal C1q deficiënte patiënten. Tevens worden studies 
beschreven naar de rol van C1q en anti-C1q antistoffen bij Neuro-Psychiatrische 
Systemische Lupus Erythematosus (NP-SLE). Daarnaast hebben we de productie 
van C1q door mestcellen en chondrocyten onderzocht.
C1q en anti-C1q antistoffen in relatie tot klinische presentatie
C1q is het herkenningsmolecuul van de klassieke route van het complementsysteem. 
Een belangrijke taak van C1q is het opruimen van immuuncomplexen en dode 
cellen. De ‘waste disposal’ theorie beschrijft hoe SLE zich ontwikkelt doordat 
immuuncomplexen en dode cellen niet kunnen worden opgeruimd vanwege de 
afwezigheid van C1q. 
Patiënten met een deficiëntie voor C1q zijn vatbaarder voor bacteriële infecties. 
Ongeveer 90% van de patiënten met een deficiëntie voor C1q ontwikkelen SLE. 
In hoofdstuk 2 wordt  een Nederlands kind beschreven dat gediagnosticeerd is met 
een C1q-deficiëntie. Door middel van het uitlezen van het genomische DNA hebben 
we kunnen vaststellen dat deze patiënt een mutatie heeft in een splitsingsplaats bij 
het gen C1qB. Opvallend is dat deze patiënt alleen te maken heeft gehad met 
bacteriële infecties, maar geen SLE heeft ontwikkeld. Omdat deze patiënt (nog) 
geen SLE heeft ontwikkeld waren wij benieuwd naar de klinische presentatie van 
andere C1qdeficiënte patiënten. 
In hoofdstuk 3 hebben we door middel van enquêtes 45 C1q-deficiënte patiënten 
in beeld gebracht. Hieruit bleek dat de klinische presentatie van C1q-deficiënte 
patiënten erg variabel is. Ongeveer 80% van deze patiënten heeft SLE ontwikkeld. 
De overige 20% van de patiënten heeft alleen bacteriële infecties of helemaal geen 
infecties en is volledig vrij van symptomen. Vanwege het variërende ziektebeeld 
is het bijzonder lastig om uit te zoeken welke therapie voor deze patiënten het 
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meest geschikt is. Daarom is het van belang dat de arts patiënten met een C1q-
deficiëntie regelmatig ziet en op deze manier een therapie kan toepassen die 
persoonsgebonden is. Uit de enquêtes bleek ook dat de kans op sterfte op jonge 
leeftijd hoog is maar, als de patiënt een volwassen leeftijd heeft bereikt, de kans op 
sterfte weer afneemt. Deze informatie geeft duidelijk aan dat het van belang is juist 
jonge kinderen met een C1q-deficiëntie goed te volgen. 
C1q-deficiëntie kan veroorzaakt worden door een mutatie in het DNA van één 
van de C1q genen. Dit kan tot gevolg hebben dat er helemaal geen C1q wordt 
geproduceerd of dat er een niet-functionele variant van C1q wordt geproduceerd. 
In hoofdstuk 4 beschrijven wij een Nederlandse patiënt die door een mutatie in het 
C1qC gen een heel lage concentratie van een andere vorm van C1q maakt, low 
molecular weight C1q (LMW-C1q). Door middel van serum analyse hebben wij dit 
LMW-C1q in beeld gebracht. Deze patiënt heeft een ernstige vorm van SLE wat zich 
uit in NP-SLE. In dit project hebben we gekeken naar de mogelijke relatie van C1q-
deficiëntie en de ontwikkeling van NP-SLE. Daarnaast hebben we de biochemische 
structuur van LMW-C1q onderzocht. Uit literatuuronderzoek blijkt dat C1r/s C4 en 
C2 deficiëntie ook een verhoogde kans geeft op het ontwikkelen van SLE, maar 
dat NP-SLE symptomen in deze groepen nooit zijn beschreven. Doordat de patiënt 
geen activatie heeft van de klassieke route, suggereren wij dat de klassieke route 
niet noodzakelijk is voor het ontwikkelen van NP-SLE, maar dat de afwezigheid van 
C1q zeker een aandeel heeft in de pathogenese van NP-SLE.
NP-SLE is een vorm van SLE, waarbij SLE patiënten neurologische en 
psychiatrische symptomen ontwikkelen. Door de aanwezigheid van ontstekingen 
en immuuncomplex deposities in de hersenen kunnen deze symptomen worden 
ontwikkeld, die ernstige gevolgen kunnen hebben. Patiënten hebben zeer variabele 
symptomen. Dit kan de diagnose van NP-SLE bemoeilijken. Immuuncomplexen die 
neerslaan in weefsels zoals in het brein zullen C1q binden en complement activeren. 
De aanwezigheid van anti-C1q antilichamen zal dit proces verder versterken. Dit 
zal zorgen voor meer complement activatie wat kan leiden tot meer schade van de 
organen. 
In hoofdstuk 5 hebben wij onderzocht of de aanwezigheid van anti-C1q 
autoantistoffen en C1q-bindende circulerende immuuncomplexen (C1q-CIC) 
associëren met NP-SLE. Door middel van serum analyses konden we aantonen 
dat patiënten met NP-SLE een hogere concentratie anti-C1q en C1q-CIC hebben 
dan gezonde individuen. Verder zagen we een associatie tussen diffuus NP-SLE 
met anti-C1q antistoffen, een verlaagde concentratie van C3 en een verlaagde 
activatie van de alternatieve route van het complementsysteem. Binnen de groep 
van patiënten die gediagnosticeerd zijn met focaal NP-SLE was een associatie 
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te zien met een lage concentratie van C4. Het verschil van de verschillende 
subgroepen van NP-SLE en de associaties met complementcomponenten kan 
worden verklaard door de mate van ontsteking die de patiënten hebben met diffuus 
NP-SLE en door de aanwezigheid van anti-fosfolipiden antistoffen in de patiënten 
met focaal NP-SLE. Daarnaast zal verder onderzoek moeten worden gedaan naar 
de mogelijke rol van andere complementcomponenten, zoals van de alternatieve 
route. De alternatieve route zou een rol kunnen spelen bij de ontwikkeling van NP-
SLE, omdat de concentratie van C3 een associatie heeft met cognitieve dysfunctie 
en psychoses in lupus patiënten. 
De productie van C1q door verschillende cellen
De voornaamste C1q producerende cellen zijn immature dendritische cellen en 
macrofagen. Deze cellen hebben eenzelfde voorloper cel namelijk de myeloïde 
voorlopercel. Mestcellen hebben ook deze voorloper cel en daarom waren wij 
nieuwsgierig of mestcellen ook C1q kunnen produceren. 
De studies beschreven in hoofdstuk 6 laten zien dat mestcellen inderdaad C1q 
kunnen produceren en uitscheiden. De productie van C1q is niet afhankelijk van de 
gelijktijdige immunologische activatie van de mestcel. Dit is bevestigd door middel 
van het analyseren van de uitscheiding van IL-8. Mestcellen staan bekend om de 
granules die binnen de cel aanwezig zijn. Het degranuleren van mestcellen is een 
bekend fenomeen in de pathogenese van allergieën. Bij deze degranulatie komen 
enzymen vrij zoals tryptase, chymase en β-hexosaminidase. C1q komt ook vrij bij 
degranuleren en kan dus mogelijk een rol spelen bij allergieën en ontstekingen 
waarbij mestcellen betrokken zijn. Met immunofluorescentie tonen wij C1q-
positieve mestcellen aan in verschillende humane weefsels zoals synovium, huid 
van psoriasis patiënten en in de normale huid. 
Complement speelt een belangrijke rol in de pathogenese van reumatische 
aandoeningen zoals reumatoïde artritis en osteoartritis. Deposities van verschillende 
complementcomponenten en complement-activatie producten zijn te vinden in het 
synovium, synoviaal vocht en in het kraakbeen van aangetaste gewrichten. In de 
jaren 90 is al beschreven dat de cellen die verantwoordelijk zijn voor de aanmaak 
van kraakbeen, chondrocyten, positief zijn voor C1q. 
In hoofdstuk 7 hebben wij onderzocht of chondrocyten inderdaad C1q kunnen 
produceren en ook uitscheiden. Wij hebben de chondrocyten gestimuleerd met 
verschillende cytokines zoals IL-1β en TNF-α. Deze cytokines zijn aanwezig in 
de gewrichten van patiënten met reumatoïde artritis en osteoartritis. Hieruit bleek 
dat IL-1β en TNF-α de RNA expressie van C1q verhoogt. Dit kan betekenen dat 
het C1q dat aanwezig is in ontstoken gewrichten, ook deels door chondrocyten 
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geproduceerd kan zijn als er sprake is van afbraak van het kraakbeen. Daarnaast 
hebben we geanalyseerd of de expressie van C1q associeert met de expressie van 
genen die coderen voor matrix-eiwitten zoals collageen types 1, 2 en 10. Door de 
chondrocyten te stimuleren met TGF-β zagen we dat de relatieve RNA expressie 
van alle types collageen was verhoogd. Deze verhoging was niet aanwezig bij de 
RNA expressie van C1q. Deze data suggereren dat de expressie van C1q en de 
expressie van matrix-opbouwende eiwitten niet aan elkaar gerelateerd zijn.
De precieze rol van C1q dat geproduceerd wordt door chondrocyten moet nog 
verder worden onderzocht.
Samenvattend: de studies beschreven in dit proefschrift laten zien dat C1q een 
belangrijke bijdrage levert bij auto-immuunziektes. Het feit dat C1q geproduceerd 
kan worden zowel door afweercellen als door niet-afweercellen suggereert dat C1q 
bij mogelijk meer lichamelijke processen mogelijk betrokken is dan eerder gedacht. 
Het begrijpen van de precieze rol van C1q in verschillende weefsels zal nieuwe 
belangrijke inzichten verschaffen op het gebied van het behandelen van patiënten 
met een auto-immuun ziekte waarbij C1q betrokken is. 
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